| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease | Phase 2/3 | NRG Oncology | <1 mi |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial | Phase 3 | NRG Oncology | <1 mi |
| Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer | N/A | SWOG Cancer Research Network | <1 mi |
| RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT | — | The Radiosurgery Society | <1 mi |
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | Phase 3 | DalCor Pharmaceuticals | <1 mi |
| Assessment of CCM in HF With Higher Ejection Fraction | N/A | Impulse Dynamics | <1 mi |
| Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study | Phase 2/3 | Kardigan, Inc. | <1 mi |
| Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation | Phase 3 | Novo Nordisk A/S | <1 mi |
| Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer | Phase 3 | Children's Oncology Group | <1 mi |
| Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | Phase 3 | NRG Oncology | <1 mi |
| Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer | N/A | NRG Oncology | <1 mi |
| Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials | N/A | Eastern Cooperative Oncology Group | <1 mi |
| ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Phase 3 | NRG Oncology | <1 mi |
| Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | Phase 2/3 | SWOG Cancer Research Network | <1 mi |
| RESPONDER-HF Trial | N/A | Corvia Medical | <1 mi |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | Phase 2 | Genmab | <1 mi |
| Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation | Phase 3 | European Myeloma Network B.V. | <1 mi |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial | Phase 3 | NRG Oncology | <1 mi |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery | Phase 3 | NRG Oncology | <1 mi |
| Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | Phase 3 | AstraZeneca | <1 mi |
| Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | Phase 2 | Hoffmann-La Roche | <1 mi |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | Phase 2 | Allogene Therapeutics | <1 mi |
| Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | Phase 1/2 | Juno Therapeutics, a Subsidiary of Celgene | <1 mi |
| Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | Phase 2 | ECOG-ACRIN Cancer Research Group | <1 mi |
| A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer | Phase 4 | Takeda | <1 mi |
| A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 3 | BeOne Medicines | <1 mi |
| Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 | Phase 3 | AstraZeneca | <1 mi |
| Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer | Phase 3 | NRG Oncology | <1 mi |
| Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | Phase 3 | Merus B.V. | <1 mi |
| Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study | Phase 2 | NRG Oncology | <1 mi |
| A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) | Phase 3 | NRG Oncology | <1 mi |
| An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | Phase 3 | AstraZeneca | <1 mi |
| Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) | Phase 3 | AstraZeneca | <1 mi |
| Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Phase 1/2 | PMV Pharmaceuticals, Inc | <1 mi |
| A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) | Phase 2/3 | SWOG Cancer Research Network | <1 mi |
| Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer | Phase 3 | NRG Oncology | <1 mi |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | Phase 2 | Iovance Biotherapeutics, Inc. | <1 mi |
| Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability | Phase 3 | NRG Oncology | <1 mi |
| S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations | Phase 3 | AstraZeneca | <1 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer | Phase 3 | AstraZeneca | <1 mi |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | <1 mi |
| Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | Phase 3 | AstraZeneca | <1 mi |
| Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | Phase 1 | Exelixis | <1 mi |
| A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease | Phase 3 | AstraZeneca | <1 mi |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 | Phase 3 | Summit Therapeutics | <1 mi |
| Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening | — | Freenome Holdings Inc. | <1 mi |
| Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Rheumatoid Arthritis Shared Decision Making | N/A | VA Office of Research and Development | <1 mi |
| Project: Every Child for Younger Patients With Cancer | — | Children's Oncology Group | <1 mi |
| A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study | Phase 2 | Children's Oncology Group | <1 mi |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations | Phase 3 | Children's Oncology Group | <1 mi |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | Phase 3 | Children's Oncology Group | <1 mi |
| A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients | Phase 3 | Children's Oncology Group | <1 mi |
| Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies | — | Children's Oncology Group | <1 mi |
| Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | Phase 3 | PedAL BCU, LLC | <1 mi |
| Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | Phase 1/2 | PedAL BCU, LLC | <1 mi |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma | Phase 3 | Children's Oncology Group | <1 mi |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | Phase 3 | Children's Oncology Group | <1 mi |
| Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | Phase 3 | Children's Oncology Group | <1 mi |
| Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) | Phase 1/2 | SWOG Cancer Research Network | <1 mi |
| A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations | Phase 2 | Sameek Roychowdhury | <1 mi |
| A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT | Phase 2 | Children's Oncology Group | <1 mi |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia | Phase 2 | Children's Oncology Group | <1 mi |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | Phase 3 | Children's Oncology Group | <1 mi |
| A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | Phase 2 | Children's Oncology Group | <1 mi |
| A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | Phase 3 | Children's Oncology Group | <1 mi |
| Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma | Phase 3 | Children's Oncology Group | <1 mi |
| A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | Phase 2 | Children's Oncology Group | <1 mi |
| Anticoagulation in ICH Survivors for Stroke Prevention and Recovery | Phase 3 | Yale University | <1 mi |
| National Collaborative to Improve Care of Children With Complex Congenital Heart Disease | — | Children's Hospital Medical Center, Cincinnati | <1 mi |
| Quality of Pediatric Resuscitation in a Multicenter Collaborative | — | Children's Hospital of Philadelphia | <1 mi |
| A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction | Phase 3 | Bayer | <1 mi |
| Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy | — | Tenaya Therapeutics | <1 mi |
| Optimal Ventilation for Cardiac Arrest | N/A | Children's Hospital of Philadelphia | <1 mi |
| A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old. | Phase 4 | Pfizer | <1 mi |
| Fontan Udenafil Exercise Longitudinal Assessment Trial - 2 | Phase 3 | Mezzion Pharma Co. Ltd | <1 mi |
| A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma | — | Children's Oncology Group | <1 mi |
| Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids | Phase 2 | AstraZeneca | <1 mi |
| Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma | Phase 3 | Children's Oncology Group | <1 mi |
| Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma | Phase 3 | Children's Oncology Group | <1 mi |
| Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol | Phase 1 | NRG Oncology | <1 mi |
| Liquid Biopsy Based NGS in Newly Diagnosed NSCLC | N/A | Charu Aggarwal | <1 mi |
| Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery | N/A | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | <1 mi |
| A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer | Phase 3 | Celgene | <1 mi |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) | Phase 3 | BeOne Medicines | <1 mi |
| Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER | Phase 2 | Canadian Cancer Trials Group | <1 mi |
| Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes | N/A | Thomas Jefferson University | <1 mi |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events | Phase 3 | Amgen | <1 mi |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) | Phase 3 | AstraZeneca | <1 mi |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | Phase 3 | Eli Lilly and Company | <1 mi |
| Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | Phase 3 | NRG Oncology | <1 mi |
| Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | <1 mi |
| Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients | — | PrECOG, LLC. | <1 mi |
| A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH | Phase 3 | Akero Therapeutics, Inc | <1 mi |
| Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation | Phase 3 | Amgen | <1 mi |
| A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge) | Phase 3 | Definium Therapeutics US, Inc. | <1 mi |
| Study to Assess the Safety and Effectiveness of NMRA-335140-501 | Phase 3 | Neumora Therapeutics, Inc. | <1 mi |
| A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) | — | Center for International Blood and Marrow Transplant Research | <1 mi |
| Clinical Trial for Integrated Care to Help At Risk Teen (iCHART) Intervention | N/A | University of Pittsburgh | <1 mi |
| EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | Phase 3 | Boehringer Ingelheim | <1 mi |
| Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation | — | Heart Rhythm Clinical and Research Solutions, LLC | <1 mi |
| Left vs Left Randomized Clinical Trial | N/A | Baylor College of Medicine | <1 mi |
| Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products | — | Medtronic | <1 mi |
| A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage) | Phase 3 | Definium Therapeutics US, Inc. | <1 mi |
| Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML | Phase 3 | Daiichi Sankyo | <1 mi |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | Phase 3 | Eli Lilly and Company | <1 mi |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study of Brenipatide in Adult Participants With Major Depressive Disorder | Phase 3 | Eli Lilly and Company | <1 mi |
| P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety | Phase 3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | <1 mi |
| Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| Testing Gene PilotLX With Latinx Cancer Patients | N/A | Fox Chase Cancer Center | <1 mi |
| Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Fabry Disease Registry & Pregnancy Sub-registry | — | Genzyme, a Sanofi Company | <1 mi |
| Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | Phase 3 | European Organisation for Research and Treatment of Cancer - EORTC | <1 mi |
| Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial | N/A | Edwards Lifesciences | <1 mi |
| Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery | N/A | Unity Health Toronto | <1 mi |
| Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer | Phase 3 | AstraZeneca | <1 mi |
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects | Phase 3 | Greenwich LifeSciences, Inc. | <1 mi |
| A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | Phase 2 | Mirum Pharmaceuticals, Inc. | <1 mi |
| Comparing Two Ways to Manage Head and Neck Lymphedema | N/A | Abramson Cancer Center at Penn Medicine | <1 mi |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | Phase 2/3 | IDEAYA Biosciences | <1 mi |
| Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA) | N/A | University of Pennsylvania | <1 mi |
| Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer | Phase 3 | Genmab | <1 mi |
| PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2 | N/A | Weill Medical College of Cornell University | <1 mi |
| First in Human Study of IMGN151 in Recurrent Gynaecological Cancers | Phase 1 | AbbVie | <1 mi |
| A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation | Phase 2 | VA Office of Research and Development | <1 mi |
| Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG) | Phase 3 | Alexion Pharmaceuticals, Inc. | <1 mi |
| Individualized (fMRI-guided) TMS Treatment for Depression | N/A | University of Pennsylvania | <1 mi |
| Investigating Dupilumab's Effect in Asthma by Genotype | Phase 4 | Boston Children's Hospital | <1 mi |
| Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer | Early 1 | Thomas Jefferson University | <1 mi |
| Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection | Phase 2/3 | Bluejay Therapeutics, Inc. | <1 mi |
| Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | Phase 1/2 | Immunocore Ltd | <1 mi |
| Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) | Phase 3 | AstraZeneca | <1 mi |
| Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS | Phase 1 | Auron Therapeutics, Inc. | <1 mi |
| A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | Phase 1/2 | Astellas Pharma Global Development, Inc. | <1 mi |
| An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer | N/A | Thomas Jefferson University | <1 mi |
| Evaluating a Bidirectional Priming Intervention for Goals-of-care Communication in Oncology | N/A | Abramson Cancer Center at Penn Medicine | <1 mi |
| Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) | N/A | ABK Biomedical | <1 mi |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | Phase 1 | AbbVie | <1 mi |
| Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) | Phase 2/3 | Novita Pharmaceuticals, Inc. | <1 mi |
| (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | Phase 2 | IDEAYA Biosciences | <1 mi |
| Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma | Phase 2 | Fox Chase Cancer Center | <1 mi |
| A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma | Phase 2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | <1 mi |
| SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | Phase 3 | Palvella Therapeutics, Inc. | <1 mi |
| Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma | Phase 1 | Institut de Recherches Internationales Servier | <1 mi |
| A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus | Phase 1 | Eli Lilly and Company | <1 mi |
| Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) | — | University of Southern California | <1 mi |
| A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE) | Phase 2 | Genentech, Inc. | <1 mi |
| Autus Valve Pivotal Study | N/A | Autus Valve Technologies, Inc. | <1 mi |
| ASCEND CSP IDE Study | N/A | Abbott Medical Devices | <1 mi |
| Nipocalimab in Moderate to Severe Sjogren's Disease | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis | N/A | University of Pennsylvania | <1 mi |
| AI-Based Fidelity Feedback to Enhance CBT | N/A | University of Pennsylvania | <1 mi |
| Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL) | Phase 1/2 | Prevail Therapeutics | <1 mi |
| Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. | Phase 1/2 | RayzeBio, Inc. | <1 mi |
| BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy | Phase 1/2 | Abramson Cancer Center at Penn Medicine | <1 mi |
| First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | Phase 1 | GlaxoSmithKline | <1 mi |
| Study of DF1001 in Patients with Advanced Solid Tumors | Phase 1/2 | Dragonfly Therapeutics | <1 mi |
| Community Support Program for Lung Cancer Screening Volume II | N/A | Abramson Cancer Center at Penn Medicine | <1 mi |
| Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | Phase 3 | AstraZeneca | <1 mi |
| AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies. | Phase 1/2 | AstraZeneca | <1 mi |
| A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer | Phase 1 | Janssen Research & Development, LLC | <1 mi |
| A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer | N/A | GOG Foundation | <1 mi |
| Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation | N/A | Thomas Jefferson University | <1 mi |
| Studying Health Outcomes After Treatment in Patients With Retinoblastoma | — | Vanderbilt-Ingram Cancer Center | <1 mi |
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | Phase 1/2 | Children's Oncology Group | <1 mi |
| Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials | Phase 3 | Celgene | <1 mi |
| A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | Incyte Corporation | <1 mi |
| An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Phase 2 | Novartis Pharmaceuticals | <1 mi |
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) | Phase 3 | Advenchen Laboratories, LLC | <1 mi |
| A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation | Phase 1 | Uma Borate | <1 mi |
| A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT | Phase 1/2 | Children's Hospital of Philadelphia | <1 mi |
| ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) | Phase 3 | Jazz Pharmaceuticals | <1 mi |
| Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors | Phase 1 | ITM Solucin GmbH | <1 mi |
| Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | Phase 1/2 | Jazz Pharmaceuticals | <1 mi |
| Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | — | Children's Hospital Medical Center, Cincinnati | <1 mi |
| A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Study of Olutasidenib and Temozolomide in HGG | Phase 2 | Rigel Pharmaceuticals | <1 mi |
| Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer | N/A | University of Michigan Rogel Cancer Center | <1 mi |
| Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer | Phase 2 | Children's Hospital of Philadelphia | <1 mi |
| [18F]FES PET/.CT in Uterine Cancer | Phase 2 | Abramson Cancer Center at Penn Medicine | <1 mi |
| Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source | Phase 1/2 | CivaTech Oncology | <1 mi |
| Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC) | — | Thomas Jefferson University | <1 mi |
| Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors | Phase 2 | Children's Hospital of Philadelphia | <1 mi |
| Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) | Phase 3 | PharmaMar | <1 mi |
| PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma | Phase 1 | Stephan Grupp MD PhD | <1 mi |
| KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis | Phase 2/3 | Kyverna Therapeutics | <1 mi |
| A Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 2 | BicycleTx Limited | <1 mi |
| Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma | Phase 1 | Ono Pharmaceutical Co. Ltd | <1 mi |
| Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy | Early 1 | Fox Chase Cancer Center | <1 mi |
| Autoimmunity After Checkpoint Blockade | — | Abramson Cancer Center at Penn Medicine | <1 mi |
| Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery | Phase 2 | ECOG-ACRIN Cancer Research Group | <1 mi |
| Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells | Phase 2/3 | Celgene | <1 mi |
| A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors | Phase 1 | Peel Therapeutics Inc | <1 mi |
| Carboplatin or Olaparib for BRcA Deficient Prostate Cancer | Phase 2 | VA Office of Research and Development | <1 mi |
| Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM | Phase 1 | University of Pennsylvania | <1 mi |
| Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) | Phase 1 | University of California, San Francisco | <1 mi |
| Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | Phase 1/2 | enGene, Inc. | <1 mi |
| A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | Phase 3 | Sumitomo Pharma Switzerland GmbH | <1 mi |
| A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD | N/A | Dana-Farber Cancer Institute | <1 mi |
| A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. | Phase 1 | Whitehawk Therapeutics, Inc. | <1 mi |
| ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors | Phase 1/2 | Immatics US, Inc. | <1 mi |
| Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients | Phase 3 | Philogen S.p.A. | <1 mi |
| CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer | Early 1 | Abramson Cancer Center at Penn Medicine | <1 mi |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | <1 mi |
| A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia | Phase 3 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | Phase 2 | CG Oncology, Inc. | <1 mi |
| A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) | Phase 3 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) | Phase 1/2 | Janssen Research & Development, LLC | <1 mi |
| Virtual Reality 3D-Surgery Modeling to Enhance Head and Neck Cancer Surgery Quality | N/A | Thomas Jefferson University | <1 mi |
| A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Bristol-Myers Squibb | <1 mi |
| Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma | Phase 2 | Abramson Cancer Center at Penn Medicine | <1 mi |
| A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma | Phase 4 | Eli Lilly and Company | <1 mi |
| Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer | N/A | Varian, a Siemens Healthineers Company | <1 mi |
| TmPSMA-02 in mCRPC | Phase 1 | University of Pennsylvania | <1 mi |
| Neoadjuvant Darovasertib in Primary Uveal Melanoma | Phase 3 | IDEAYA Biosciences | <1 mi |
| A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors | Phase 1/2 | Crinetics Pharmaceuticals Inc. | <1 mi |
| Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) | Phase 1/2 | Recursion Pharmaceuticals Inc. | <1 mi |
| CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy | Phase 1 | University of Pennsylvania | <1 mi |
| Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer | Phase 2 | EXACT Therapeutics AS | <1 mi |
| A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer | Phase 2 | Ono Pharmaceutical Co. Ltd | <1 mi |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma | N/A | Melanoma and Skin Cancer Trials Limited | <1 mi |
| Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer | Phase 2/3 | NRG Oncology | <1 mi |
| AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | Phase 3 | AstraZeneca | <1 mi |
| FTT PET/CT in Metastatic Prostate Cancer | — | Abramson Cancer Center at Penn Medicine | <1 mi |
| Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis | N/A | Abramson Cancer Center at Penn Medicine | <1 mi |
| A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | Phase 1/2 | Artios Pharma Ltd | <1 mi |
| A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis | Phase 1 | Janssen Research & Development, LLC | <1 mi |
| Combination Therapy for the Treatment of Diffuse Midline Gliomas | Phase 2 | University of California, San Francisco | <1 mi |
| Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia | N/A | University of Colorado, Denver | <1 mi |
| Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors | Phase 1/2 | MBrace Therapeutics | <1 mi |
| Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy | — | St. Jude Children's Research Hospital | <1 mi |
| Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma | Phase 1/2 | Children's Oncology Group | <1 mi |
| Phase IB/II of CPX-351 for Relapse Prevention in AML | Phase 1/2 | Georgetown University | <1 mi |
| P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma | Phase 1 | Poseida Therapeutics, Inc. | <1 mi |
| Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Amgen | <1 mi |
| Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC | Phase 2 | Massachusetts General Hospital | <1 mi |
| Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma | Phase 2 | Fox Chase Cancer Center | <1 mi |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | Phase 1/2 | Turning Point Therapeutics, Inc. | <1 mi |
| Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk | — | Abramson Cancer Center at Penn Medicine | <1 mi |
| PHL Treatment in Pancreatic Cancer | Early 1 | Fox Chase Cancer Center | <1 mi |
| A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | Phase 3 | Regeneron Pharmaceuticals | <1 mi |
| Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| Prostate Tissue BioBank | — | Abramson Cancer Center at Penn Medicine | <1 mi |
| A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | Phase 1/2 | Chimeric Therapeutics | <1 mi |
| DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer | Phase 3 | AstraZeneca | <1 mi |
| A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab | — | City of Hope Medical Center | <1 mi |
| Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL | Phase 3 | Soligenix | <1 mi |
| CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | Phase 2 | TORL Biotherapeutics, LLC | <1 mi |
| Childhood Cancer Predisposition Study (CCPS) | — | Emory University | <1 mi |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) | Phase 1 | Caribou Biosciences, Inc. | <1 mi |
| Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| IMmunotherapy: Prospective Assessment of Cannabis Treatment in Cancer | — | State University of New York at Buffalo | <1 mi |
| Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer | Phase 3 | Surgimab | <1 mi |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | Phase 1 | Therapeutic Advances in Childhood Leukemia Consortium | <1 mi |
| Trial of Ixazomib for Kaposi Sarcoma | Phase 2 | AIDS Malignancy Consortium | <1 mi |
| An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors | Phase 1 | BeOne Medicines | <1 mi |
| Evaluation of Grief Therapy Approaches for Bereaved Parents | N/A | University of Miami | <1 mi |
| Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer | Phase 2 | Fox Chase Cancer Center | <1 mi |
| Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support | N/A | University of Pennsylvania | <1 mi |
| Massage Impact on Sleep in Pediatric Oncology | N/A | Children's Hospital of Philadelphia | <1 mi |
| Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema | N/A | Abramson Cancer Center at Penn Medicine | <1 mi |
| A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL) | Phase 1 | Thomas Jefferson University | <1 mi |
| Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma | — | Fox Chase Cancer Center | <1 mi |
| A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy | Phase 2 | Stemline Therapeutics, Inc. | <1 mi |
| Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | Phase 1 | Inhibrx Biosciences, Inc | <1 mi |
| TmCD19-IL18 in CD19+ Cancers | Phase 1 | University of Pennsylvania | <1 mi |
| First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | <1 mi |
| Epcoritamab-CAR T Cells for Large B-cell Lymphomas | Phase 2 | Abramson Cancer Center at Penn Medicine | <1 mi |
| A Study of ZL-1310 in Participants With Selected Solid Tumors | Phase 1/2 | Zai Lab (Shanghai) Co., Ltd. | <1 mi |
| Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma | Phase 2 | Fox Chase Cancer Center | <1 mi |
| Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | Phase 1 | Sabine Mueller, MD, PhD | <1 mi |
| Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors | Phase 1/2 | Daiichi Sankyo | <1 mi |
| Communication About Sexual Health in Gynecologic Cancer | N/A | Fox Chase Cancer Center | <1 mi |
| Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia | N/A | Massachusetts General Hospital | <1 mi |
| A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy | Phase 1 | Children's Oncology Group | <1 mi |
| Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) | Phase 1/2 | Cellectis S.A. | <1 mi |
| A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma | — | Aura Biosciences | <1 mi |
| Parathyroid Tumor Clonal Status | — | Washington University School of Medicine | <1 mi |
| Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery | Phase 1 | Ryan Carey | <1 mi |
| A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors | Phase 1 | BeiGene | <1 mi |
| JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC | Phase 3 | Johnson & Johnson Enterprise Innovation Inc. | <1 mi |
| Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs) | — | National Cancer Institute (NCI) | <1 mi |
| Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC | Early 1 | Children's Hospital of Philadelphia | <1 mi |
| Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma | Phase 2 | Northwestern University | <1 mi |
| Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations | Phase 2 | Rana McKay, MD | <1 mi |
| Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors | Phase 1 | Debiopharm International SA | <1 mi |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Phase 1 | Nurix Therapeutics, Inc. | <1 mi |
| TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | Phase 2 | American Society of Clinical Oncology | <1 mi |
| Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | Phase 3 | Priothera SAS | <1 mi |
| Reducing Urban Cervical Cancer Disparities | N/A | Fox Chase Cancer Center | <1 mi |
| PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors | Phase 1/2 | Theodore Laetsch | <1 mi |
| In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma | Early 1 | Heather Wachtel | <1 mi |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | Phase 2/3 | Global Coalition for Adaptive Research | <1 mi |
| A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors | Phase 1 | Genentech, Inc. | <1 mi |
| A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma | Phase 2 | Jazz Pharmaceuticals | <1 mi |
| Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study | N/A | M.D. Anderson Cancer Center | <1 mi |
| The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System | N/A | May Health | <1 mi |
| Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) | Phase 3 | Polaris Group | <1 mi |
| Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) | — | Alexion Pharmaceuticals, Inc. | <1 mi |
| Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| "Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)" | N/A | University of Alabama at Birmingham | <1 mi |
| Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms | Phase 1 | Janssen Research & Development, LLC | <1 mi |
| PopSci CHW4CervixHealth | N/A | Thomas Jefferson University | <1 mi |
| Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity | Phase 2 | Seattle Children's Hospital | <1 mi |
| VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | Phase 1/2 | University of Texas Southwestern Medical Center | <1 mi |
| Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | <1 mi |
| A Study of PYX-201 in Advanced Solid Tumors | Phase 1 | Pyxis Oncology, Inc | <1 mi |
| Comparing Numbing Techniques in Mohs Micrographic Surgery | N/A | Abramson Cancer Center at Penn Medicine | <1 mi |
| Efficacy and Safety of the CG-100 Intraluminal Bypass Device | N/A | Colospan Ltd. | <1 mi |
| Limited-duration Teclistamab | Phase 2 | Abramson Cancer Center at Penn Medicine | <1 mi |
| Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II) | Phase 3 | Fox Chase Cancer Center | <1 mi |
| A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | Phase 1 | Kura Oncology, Inc. | <1 mi |
| NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies | Phase 1/2 | Novita Pharmaceuticals, Inc. | <1 mi |
| Adaptive Radiation Boost for Rectal Cancer | Phase 1 | Fox Chase Cancer Center | <1 mi |
| A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG | Early 1 | Children's Hospital of Philadelphia | <1 mi |
| Li-Fraumeni Syndrome/TP53 Biobank | — | Abramson Cancer Center at Penn Medicine | <1 mi |
| Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer | — | Gynecologic Oncology Group | <1 mi |
| A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma | Phase 1/2 | Ravi Amaravadi, MD | <1 mi |
| Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body | — | Bayer | <1 mi |
| Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery | Phase 2 | Thomas Jefferson University | <1 mi |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | Phase 2 | AbbVie | <1 mi |
| Self-Management for Head and Neck Lymphedema and Fibrosis [PROMISE Trial] | N/A | Abramson Cancer Center at Penn Medicine | <1 mi |
| Venetoclax + Azacitidine vs. Induction Chemotherapy in AML | Phase 2 | Massachusetts General Hospital | <1 mi |
| Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer | N/A | Fox Chase Cancer Center | <1 mi |
| Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04) | N/A | National Cancer Institute (NCI) | <1 mi |
| Study of AZD0754 in Participants With Metastatic Prostate Cancer | Phase 1/2 | AstraZeneca | <1 mi |
| Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma | Early 1 | Abramson Cancer Center at Penn Medicine | <1 mi |
| The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study | N/A | Vivek Narayan | <1 mi |
| Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| Videos to Aid Decision Making for Fibroid Treatment | N/A | University of Pennsylvania | <1 mi |
| A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer | Phase 1/2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| FTT PET/CT in Pancreatic Neuroendocrine Tumors | Phase 1 | Abramson Cancer Center at Penn Medicine | <1 mi |
| A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) | Phase 1/2 | Nuvalent Inc. | <1 mi |
| BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) | Phase 1/2 | BioInvent International AB | <1 mi |
| Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | Phase 1 | Fox Chase Cancer Center | <1 mi |
| SynKIR-310 for Relapsed/Refractory B-NHL | Phase 1 | Verismo Therapeutics | <1 mi |
| A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL) | Phase 1/2 | Terns, Inc. | <1 mi |
| Pancreatic Cancer Early Detection Consortium | — | Arbor Research Collaborative for Health | <1 mi |
| EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection | Phase 2 | New York Medical College | <1 mi |
| AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma | Phase 1/2 | AstraZeneca | <1 mi |
| Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients | — | Mayo Clinic | <1 mi |
| Cannabis Use and Outcomes in Black and White Patients With Cancer | — | State University of New York at Buffalo | <1 mi |
| International Registry for Men With Advanced Prostate Cancer (IRONMAN) | — | Prostate Cancer Clinical Trials Consortium | <1 mi |
| A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors | Phase 1/2 | Takeda | <1 mi |
| GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma | Phase 1 | Stephan Grupp MD PhD | <1 mi |
| Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer | Phase 3 | NRG Oncology | <1 mi |
| Mozobil for Autologous Hematopoietic Stem Cell Transplantation | Phase 2 | Thomas Jefferson University | <1 mi |
| Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE) | Phase 2 | Children's Hospital of Philadelphia | <1 mi |
| A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | <1 mi |
| A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib | Phase 4 | Eli Lilly and Company | <1 mi |
| Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma | N/A | University of Southern California | <1 mi |
| A Study of Tarlatamab for People With Prostate Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 | Phase 1 | Jazz Pharmaceuticals | <1 mi |
| FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors | Phase 1 | Fate Therapeutics | <1 mi |
| All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma | Phase 2 | Stephen Bagley, MD, MSCE | <1 mi |
| A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence | Phase 2 | Philogen S.p.A. | <1 mi |
| Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study | — | M.D. Anderson Cancer Center | <1 mi |
| A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors | Phase 1 | Context Therapeutics Inc. | <1 mi |
| Communication Strategies to Increase HPV Vaccination Intention | N/A | University of Pennsylvania | <1 mi |
| TumorGlow Intraoperative Molecular Imaging (IMI) | Phase 1/2 | University of Pennsylvania | <1 mi |
| A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer | Phase 1 | Fox Chase Cancer Center | <1 mi |
| Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy | N/A | Thomas Jefferson University | <1 mi |
| WBSI Guided Personalized Delivery of TTFields | N/A | Abramson Cancer Center at Penn Medicine | <1 mi |
| Collection of Circulating Biomarkers in Pancreatic Cancer | — | Abramson Cancer Center at Penn Medicine | <1 mi |
| The Erector Spinae Plane Block For Gastrointestinal Malignancy Pain Treatment (EGIPT) | N/A | Abramson Cancer Center at Penn Medicine | <1 mi |
| A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) | Phase 2 | Wugen, Inc. | <1 mi |
| A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| PROton Therapy for Post Surgical Treatment of GYNecologic Cancer | Phase 2 | Abramson Cancer Center at Penn Medicine | <1 mi |
| Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. | Phase 2/3 | Novartis Pharmaceuticals | <1 mi |
| A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer | Phase 1/2 | ImmunityBio, Inc. | <1 mi |
| A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors | Phase 1 | Johnson & Johnson Enterprise Innovation Inc. | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | Phase 3 | Incyte Corporation | <1 mi |
| Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas | Phase 1 | Children's Hospital of Philadelphia | <1 mi |
| A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) | Phase 1 | Autolus Limited | <1 mi |
| Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults | Phase 2 | Sabine Mueller, MD, PhD | <1 mi |
| A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours | Phase 1/2 | Ipsen | <1 mi |
| From Screening to Support: A Multi-Method Analysis of HRSN Integration in Cancer Care | — | Thomas Jefferson University | <1 mi |
| JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | Phase 1 | Jazz Pharmaceuticals | <1 mi |
| The Radiation Oncology Registry and Biosample Repository | — | Abramson Cancer Center at Penn Medicine | <1 mi |
| A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | Phase 2 | Fore Biotherapeutics | <1 mi |
| eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer | N/A | Abramson Cancer Center at Penn Medicine | <1 mi |
| Pan Tumor Rollover Study | Phase 2 | Bristol-Myers Squibb | <1 mi |
| STimulation to Activate RespIration | N/A | Lungpacer Medical Inc. | <1 mi |
| Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors | Phase 2 | Fox Chase Cancer Center | <1 mi |
| Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma | Phase 3 | Regeneron Pharmaceuticals | <1 mi |
| A Study Evaluating ANV600 Single Agent or in Combination with Pembrolizumab in Participants with Advanced Solid Tumors (EXPAND-1) | Phase 1/2 | Anaveon AG | <1 mi |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | Phase 3 | Immatics US, Inc. | <1 mi |
| Re-Engaging AYA Survivors in Cancer-Related Healthcare | N/A | Children's Hospital of Philadelphia | <1 mi |
| Topical Anti-Androgens in Pilonidal Sinus Disease | Phase 2 | University of Pennsylvania | <1 mi |
| Study of LYL314 in Aggressive Large B-Cell Lymphoma | Phase 1/2 | Lyell Immunopharma, Inc. | <1 mi |
| A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC) | — | Tempus AI | <1 mi |
| Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) | Phase 3 | Amgen | <1 mi |
| Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Hoffmann-La Roche | <1 mi |
| MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma | Phase 1/2 | Perspective Therapeutics | <1 mi |
| A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors | Phase 1/2 | Biohaven Therapeutics Ltd. | <1 mi |
| Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer | Phase 1 | Abramson Cancer Center at Penn Medicine | <1 mi |
| SLV-324 Treatment of Metastatic Solid Tumors | Phase 1 | Solve Therapeutics | <1 mi |
| Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy | — | Massachusetts General Hospital | <1 mi |
| Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | Phase 3 | Cartesian Therapeutics | <1 mi |
| The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis | N/A | Ad scientiam | <1 mi |
| Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | Phase 1/2 | Novartis Pharmaceuticals | <1 mi |
| A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation | Phase 1 | TScan Therapeutics, Inc. | <1 mi |
| Lurbinectedin in FET-Fused Tumors | Phase 1/2 | Children's Hospital of Philadelphia | <1 mi |
| NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial | Phase 2 | New Approaches to Neuroblastoma Therapy Consortium | <1 mi |
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | Phase 3 | Kura Oncology, Inc. | <1 mi |
| A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Phase 2 | Acrivon Therapeutics | <1 mi |
| A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) | Phase 3 | AstraZeneca | <1 mi |
| Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | Phase 1/2 | BeOne Medicines | <1 mi |
| Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 | Phase 2 | University of Alabama at Birmingham | <1 mi |
| Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Childhood Cancer Survivor Study | — | St. Jude Children's Research Hospital | <1 mi |
| Adoptive Cell Therapy Long-term Follow-up (LTFU) Study | Phase 1 | USWM CT, LLC | <1 mi |
| A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | Phase 1/2 | AstraZeneca | <1 mi |
| CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | Phase 1/2 | Curis, Inc. | <1 mi |
| A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | Phase 1/2 | Syndax Pharmaceuticals | <1 mi |
| Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma | Phase 2 | Abramson Cancer Center at Penn Medicine | <1 mi |
| A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | Phase 3 | AVEO Pharmaceuticals, Inc. | <1 mi |
| Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma | Early 1 | Fox Chase Cancer Center | <1 mi |
| CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT | N/A | Children's Hospital of Philadelphia | <1 mi |
| High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery | N/A | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | <1 mi |
| Physiologic MR Imaging of Salivary Gland Tumors | N/A | Abramson Cancer Center at Penn Medicine | <1 mi |
| A Study of Emapalumab for Pediatric Aplastic Anemia | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70) | — | Abramson Cancer Center at Penn Medicine | <1 mi |
| Co-administration of CART22-65s and huCART19 for B-ALL | Phase 1/2 | Stephan Grupp MD PhD | <1 mi |
| Targeted Therapy to Increase RAI Uptake in Metastatic DTC | — | Children's Hospital of Philadelphia | <1 mi |
| Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma | N/A | University of California, San Francisco | <1 mi |
| Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana | N/A | Abramson Cancer Center at Penn Medicine | <1 mi |
| Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | Phase 1 | St. Jude Children's Research Hospital | <1 mi |
| Tazemetostat and Palbociclib With CPX-351for R/R AML | Phase 1 | Thomas Jefferson University | <1 mi |
| Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | Phase 1/2 | CellCentric Ltd. | <1 mi |
| A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | Phase 1/2 | Sumitomo Pharma America, Inc. | <1 mi |
| Shield Post-Approval Study Protocol | — | Guardant Health, Inc. | <1 mi |
| EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma | Phase 3 | NovoCure GmbH | <1 mi |
| Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | Phase 2 | Alliance for Clinical Trials in Oncology | <1 mi |
| Neuroblastoma Biology Study | — | New Approaches to Neuroblastoma Therapy Consortium | <1 mi |
| Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma | Phase 1/2 | Genfit | <1 mi |
| Adaptive Radiation for Abdominopelvic Metastases | Phase 1 | Fox Chase Cancer Center | <1 mi |
| A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | Phase 2/3 | Linnaeus Therapeutics, Inc. | <1 mi |
| A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction | Phase 1/2 | Roswell Park Cancer Institute | <1 mi |
| Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) | Phase 1/2 | Stephan Grupp MD PhD | <1 mi |
| Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | Phase 1/2 | Nationwide Children's Hospital | <1 mi |
| 18F-Fluciclovine PET-MRI in High-grade Glioma | Early 1 | Children's Hospital of Philadelphia | <1 mi |
| Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma | Early 1 | Abramson Cancer Center at Penn Medicine | <1 mi |
| FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 | Phase 1 | Eli Lilly and Company | <1 mi |
| A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | Phase 1 | K36 Therapeutics, Inc. | <1 mi |
| Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer | Phase 2 | University of Pennsylvania | <1 mi |
| A Study of EP0031 in Patients With Advanced RET-altered Malignancies | Phase 1/2 | Ellipses Pharma | <1 mi |
| Collection of Samples USOPTIVAL Study | — | Universal Diagnostics | <1 mi |
| A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma | Phase 3 | Ivy Brain Tumor Center | <1 mi |
| Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder | Phase 1/2 | Noah Hahn, M.D. | <1 mi |
| A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | Phase 2/3 | Replimune Inc. | <1 mi |
| Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL | Phase 2 | AstraZeneca | <1 mi |
| Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study | — | University of Washington | <1 mi |
| Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma | N/A | Dana-Farber Cancer Institute | <1 mi |
| A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | Phase 1 | Kura Oncology, Inc. | <1 mi |
| A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy | Phase 3 | GlaxoSmithKline | <1 mi |
| Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Phase 1/2 | IDEAYA Biosciences | <1 mi |
| A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors | Phase 2 | Day One Biopharmaceuticals, Inc. | <1 mi |
| Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | Phase 3 | Immunocore Ltd | <1 mi |
| Genomic Risk in Retroperitoneal Sarcoma | — | Fox Chase Cancer Center | <1 mi |
| Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | Phase 1/2 | Disc Medicine, Inc | <1 mi |
| Pencil Beam Scanning in Patients With Renal Tumors | Early 1 | Children's Hospital of Philadelphia | <1 mi |
| PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC | Early 1 | Presage Biosciences | <1 mi |
| Neurocognition in Congenital Central Hypoventilation Syndrome (CCHS) | — | Debra Weese-Mayer | <1 mi |
| Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients | N/A | Thomas Jefferson University | <1 mi |
| Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer | Phase 2/3 | VA Office of Research and Development | <1 mi |
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | Phase 3 | Verastem, Inc. | <1 mi |
| A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | <1 mi |
| High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer | N/A | Fox Chase Cancer Center | <1 mi |
| Dental Implant Healing With TNF-Alpha Inhibitors | N/A | University of Pennsylvania | <1 mi |
| A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | Phase 4 | Janssen Research & Development, LLC | <1 mi |
| Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors | Phase 1/2 | Pyxis Oncology, Inc | <1 mi |
| Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT | Phase 1 | Abramson Cancer Center at Penn Medicine | <1 mi |
| Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | Early 1 | Nationwide Children's Hospital | <1 mi |
| CAR-T Followed by Bispecific Antibodies | Phase 2 | Abramson Cancer Center at Penn Medicine | <1 mi |
| A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma | Early 1 | AIDS Malignancy Consortium | <1 mi |
| Implementing the NYU Electronic Patient Visit Assessment (ePVA) for Head and Neck Cancer In Rural and Urban Populations | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| Synovial Sarcoma Registry / Biospecimen Repository | — | Children's Hospital of Philadelphia | <1 mi |
| CARE Study: Cancer, Asian Americans, and Relationship Enrichment | N/A | Fox Chase Cancer Center | <1 mi |
| Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network | — | Thomas Jefferson University | <1 mi |
| Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation | Phase 2 | john eisenbrey | <1 mi |
| A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 | Phase 2 | Healx Limited | <1 mi |
| Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma | Phase 1 | Stephan Grupp MD PhD | <1 mi |
| CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML | Phase 1 | University of Pennsylvania | <1 mi |
| SPEARHEAD-3 Pediatric Study | Phase 1/2 | USWM CT, LLC | <1 mi |
| A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Phase 2/3 | Daiichi Sankyo | <1 mi |
| Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer | Phase 2 | Matthew Galsky | <1 mi |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2 | SWOG Cancer Research Network | <1 mi |
| International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) | Phase 3 | Institute of Cancer Research, United Kingdom | <1 mi |
| Neoadjuvant Tebentafusp for Uveal Melanoma | Phase 2 | Thomas Jefferson University | <1 mi |
| Evaluation of Uterine Fibroids by CEUS and SHAPE Pre and Post UAE | Phase 2 | Thomas Jefferson University | <1 mi |
| Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors | — | Azienda Ospedaliero-Universitaria Careggi | <1 mi |
| Assessment of Geriatric Evaluations Impact on New AML Guidance | — | Abramson Cancer Center at Penn Medicine | <1 mi |
| Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma | Phase 2 | Regeneron Pharmaceuticals | <1 mi |
| Home Blood Transfusions | N/A | Thomas Jefferson University | <1 mi |
| Implementation of eHealth Delivery Alternatives for Cancer Genetic Testing for Hereditary Cancer (eREACH3) | — | Abramson Cancer Center at Penn Medicine | <1 mi |
| A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias | Phase 1 | Crossbow Therapeutics, Inc. | <1 mi |
| A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Phase 2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | <1 mi |
| Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant | Phase 2 | Nationwide Children's Hospital | <1 mi |
| A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma | Phase 3 | Aura Biosciences | <1 mi |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | Phase 3 | RayzeBio, Inc. | <1 mi |
| A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Assessing Patient Satisfaction and Confidence After Use of Educational Video to Augment Surgical Consent for Thyroid Surgery | N/A | Thomas Jefferson University | <1 mi |
| A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases | Phase 3 | Rakuten Medical, Inc. | <1 mi |
| Suprachoroidal Administration in Subjects With Metastases to the Choroid | Phase 2 | Aura Biosciences | <1 mi |
| A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies | Phase 1/2 | Deciphera Pharmaceuticals, LLC | <1 mi |
| Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE) | — | Fox Chase Cancer Center | <1 mi |
| Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma | Phase 1 | New York Medical College | <1 mi |
| A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | Phase 2 | AbbVie | <1 mi |
| A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma | Phase 1/2 | ModernaTX, Inc. | <1 mi |
| A Global Study of the PETAL Consortium | — | Massachusetts General Hospital | <1 mi |
| Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer | Phase 1 | Amgen | <1 mi |
| SNV1521 in Participants with Advanced Solid Tumors | Phase 1 | Synnovation Therapeutics, Inc. | <1 mi |
| realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL | — | Incyte Corporation | <1 mi |
| Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002) | Phase 1 | Karen Ballen, MD | <1 mi |
| S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors | Phase 1/2 | Shionogi | <1 mi |
| Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy | Phase 2 | Abramson Cancer Center at Penn Medicine | <1 mi |
| Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies | — | Abramson Cancer Center at Penn Medicine | <1 mi |
| PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability | — | University of Pennsylvania | <1 mi |
| A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases | Phase 1 | Arcellx, Inc. | <1 mi |
| Healthy Volunteers Study | — | Abramson Cancer Center at Penn Medicine | <1 mi |
| A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | Phase 3 | AstraZeneca | <1 mi |
| Hypofractionated WPPT With HDR Boost | Phase 2 | Abramson Cancer Center at Penn Medicine | <1 mi |
| A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients | Phase 3 | Merus B.V. | <1 mi |
| Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma | — | Case Western Reserve University | <1 mi |
| Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix | N/A | Varian, a Siemens Healthineers Company | <1 mi |
| A Study of AT-02 in Subjects With Systemic Amyloidosis. | Phase 2 | Attralus, Inc. | <1 mi |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | Phase 1 | ADC Therapeutics S.A. | <1 mi |
| Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma | Phase 2/3 | Daiichi Sankyo | <1 mi |
| A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC | Phase 2 | CytoDyn, Inc. | <1 mi |
| Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis | Phase 1 | Attralus, Inc. | <1 mi |
| Eatwell Clinical Trial (R01) | N/A | Drexel University | <1 mi |
| First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors | Phase 1 | IDRx Inc. - A GSK Company | <1 mi |
| First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors | Phase 1 | CDR-Life AG | <1 mi |
| Understanding the Preferences and Views of Older Adults on the Use of Geriatric and Objective Functional Assessments for Cancer Treatment Planning. | N/A | Fox Chase Cancer Center | <1 mi |
| A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | Phase 3 | Bristol-Myers Squibb | <1 mi |
| A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | Phase 1/2 | Nuvalent Inc. | <1 mi |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients | Phase 1 | Fox Chase Cancer Center | <1 mi |
| Combined Oral Contraceptive Pill and Resistance Starch | Phase 2 | University of Pennsylvania | <1 mi |
| An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib | Phase 2 | University of Colorado, Denver | <1 mi |
| ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors | Phase 1 | Sabine Mueller, MD, PhD | <1 mi |
| Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors | Phase 2/3 | Exelixis | <1 mi |
| A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer | Phase 3 | Eli Lilly and Company | <1 mi |
| SNV4818 in Participants With Advanced Solid Tumors | Phase 1/2 | Pikavation Therapeutics, Inc. | <1 mi |
| Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents | Phase 2 | Joshua Zeidner | <1 mi |
| CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL) | Phase 1 | Vittoria Biotherapeutics | <1 mi |
| Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL | Phase 2 | Etan Orgel | <1 mi |
| A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer | Phase 2 | Eli Lilly and Company | <1 mi |
| A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | Early 1 | Nationwide Children's Hospital | <1 mi |
| Excision of Lymph Node Trial (EXCILYNT) (Mel69) | N/A | Craig L Slingluff, Jr | <1 mi |
| PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma | Phase 2 | Nationwide Children's Hospital | <1 mi |
| Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Targeted Pediatric High-Grade Glioma Therapy | — | Nationwide Children's Hospital | <1 mi |
| TERPS Trial for de Novo Oligometastic Prostate Cancer | Phase 2 | University of Maryland, Baltimore | <1 mi |
| A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis | Phase 2/3 | Janssen Research & Development, LLC | <1 mi |
| Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer | Phase 1 | Nerviano Medical Sciences | <1 mi |
| Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | Phase 1 | Janux Therapeutics | <1 mi |
| Gastroparesis Registry 4 | — | Johns Hopkins Bloomberg School of Public Health | <1 mi |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | Phase 3 | Eli Lilly and Company | <1 mi |
| Closed Loop and Education for Hypoglycemia Awareness Restoration | N/A | Milton S. Hershey Medical Center | <1 mi |
| A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes | Phase 2 | Zucara Therapeutics Inc. | <1 mi |
| Transformative Research in Diabetic Nephropathy | — | University of Pennsylvania | <1 mi |
| A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes | Phase 3 | Sanofi | <1 mi |
| Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes | N/A | Thomas Jefferson University | <1 mi |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | Phase 3 | Eli Lilly and Company | <1 mi |
| Nonhealing Diabetic Foot Ulcers Treated With Standard of Care (SOC) Alone or Standard of Care and Amnion-Intermediate-Chorion (AIC) | Phase 4 | Cellution Biologics | <1 mi |
| Novel Glaucoma Diagnostics | — | Wills Eye | <1 mi |
| Different Doses of Naronapride Vs. Placebo in Gastroparesis | Phase 2 | Dr. Falk Pharma GmbH | <1 mi |
| Bionic Pancreas in CFRD | Phase 3 | Jaeb Center for Health Research | <1 mi |
| DISCOVERY of Risk Factors for Type 2 Diabetes in Youth | — | George Washington University | <1 mi |
| DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes | Phase 4 | Ohio State University | <1 mi |
| A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults | Phase 3 | Eli Lilly and Company | <1 mi |
| Sleep and Glycemic Control in Type 2 Diabetes Adolescents | N/A | Children's Hospital of Philadelphia | <1 mi |
| A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes | Phase 2 | Hoffmann-La Roche | <1 mi |
| Phenotyping Genetic Risk for Type 2 Diabetes | N/A | University of Pennsylvania | <1 mi |
| Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes | Phase 2/3 | Jaeb Center for Health Research | <1 mi |
| T1D Pregnancy & Me | — | Jaeb Center for Health Research | <1 mi |
| Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery | N/A | Jaeb Center for Health Research | <1 mi |
| FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS) | Phase 2 | Sanofi | <1 mi |
| A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) | Phase 3 | Eli Lilly and Company | <1 mi |
| Beta-cell Response to Incretin Hormones in Cystic Fibrosis | N/A | University of Pennsylvania | <1 mi |
| CGM for the Early Detection and Management of Hyperglycemia in Pregnancy | N/A | Jaeb Center for Health Research | <1 mi |
| A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes | Phase 3 | Vertex Pharmaceuticals Incorporated | <1 mi |
| Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM) | — | Jaeb Center for Health Research | <1 mi |
| A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | Phase 3 | Novo Nordisk A/S | <1 mi |
| SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes | Phase 2 | SAb Biotherapeutics, Inc. | <1 mi |
| A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) | Phase 3 | Eli Lilly and Company | <1 mi |
| GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance | Phase 2 | University of Pennsylvania | <1 mi |
| Registry for Stage 2 Type 1 Diabetes | — | Sanofi | <1 mi |
| The GRoceries Aimed at Increasing Nutrition Study | N/A | University of Pennsylvania | <1 mi |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Phase 3 | Boehringer Ingelheim | <1 mi |
| An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant | Phase 3 | Vertex Pharmaceuticals Incorporated | <1 mi |
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | Phase 3 | vTv Therapeutics | <1 mi |
| Transformative Research in Diabetic Nephropathy 2.0 | — | University of Pennsylvania | <1 mi |
| Dorzagliatin in Pancreatic Insufficient Cystic Fibrosis | Phase 1 | University of Pennsylvania | <1 mi |
| Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2) | N/A | Thomas Jefferson University | <1 mi |
| CGM for Management of Type 2 Diabetes in Pregnancy | N/A | University of Alabama at Birmingham | <1 mi |
| Get ActivE Study for At-risk Youth | N/A | University of Pittsburgh | <1 mi |
| Improving Mood for Adolescents Through Teaming With End-Users in Routine Care (The iMATTER Project) | N/A | Children's Hospital of Philadelphia | <1 mi |
| RISE Versus Advocacy-based Enhanced Care as Usual for Patients Experiencing IPV | N/A | Boston University | <1 mi |
| Transdiagnostic Sleep and Circadian Intervention + Bright Light in Adolescents With Elevated Depression (TranS-C+BL) | N/A | University of Pittsburgh | <1 mi |
| Virtual Patient Navigation During a Pandemic | N/A | Children's Hospital of Philadelphia | <1 mi |
| Taking Action for College Students | N/A | Temple University | <1 mi |
| A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD) | — | Janssen Research & Development, LLC | <1 mi |
| Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | Phase 3 | Intra-Cellular Therapies, Inc. | <1 mi |
| Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND) | N/A | Abbott Medical Devices | <1 mi |
| Disentangling the Role of Depression in Hypersomnia | — | University of Pennsylvania | <1 mi |
| Neurofeedback to Treat Depression - 2 | N/A | University of Pennsylvania | <1 mi |
| Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder | Phase 3 | Neumora Therapeutics, Inc. | <1 mi |
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | Phase 3 | Cybin IRL Limited | <1 mi |
| Healing at Home 2.0 - Enhanced Chat Tool for Lowering Postpartum Depression | N/A | University of Pennsylvania | <1 mi |
| Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Getting Out of the House: Using Behavioral Activation to Increase Community Participation | N/A | Temple University | <1 mi |
| A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| Antidepressant Adherence for Depressed Adults in Primary Care | N/A | University of Pennsylvania | <1 mi |
| A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression | N/A | LivaNova | <1 mi |
| A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) | Phase 2 | atai Therapeutics, Inc. | <1 mi |
| A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder | Phase 2 | Syndeio Biosciences, Inc | <1 mi |
| Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease | Phase 2 | Celgene | <1 mi |
| PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620 | Phase 3 | University of Pennsylvania | <1 mi |
| Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia | — | GAP Innovations, PBC | <1 mi |
| Longitudinal Early-onset Alzheimer's Disease Study Protocol | — | Indiana University | <1 mi |
| Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders | N/A | University of Michigan | <1 mi |
| Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A | Early 1 | University of Pennsylvania | <1 mi |
| Using the EHR to Advance Genomic Medicine Across a Diverse Health System | N/A | University of Pennsylvania | <1 mi |
| Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU) | — | University of Pennsylvania | <1 mi |
| Neuroinflammation Imaging in AD | Early 1 | University of Pennsylvania | <1 mi |
| UPenn Observational Research Repository on Neurodegenerative Disease | — | University of Pennsylvania | <1 mi |
| A Study to Investigate Why Overweight People Regain Weight After Losing Weight in a Behavioral Weight Loss Program | N/A | University of Pittsburgh | <1 mi |
| AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight | Phase 3 | Novo Nordisk A/S | <1 mi |
| A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) | Phase 1 | Solid Biosciences Inc. | <1 mi |
| Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | Phase 3 | AstraZeneca | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy | Phase 3 | Lexicon Pharmaceuticals | <1 mi |
| Saline Enhanced Radiofrequency (SERF) Needle Ablation for Refractory VT | N/A | Thermedical, Inc. | <1 mi |
| Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure | N/A | McMaster University | <1 mi |
| Intra-aortic Balloon Counterpulsation (IABC) Compliance | — | Thomas Jefferson University | <1 mi |
| Beta-blocker Administration for Cardiomyocyte Division | Phase 1 | Weill Medical College of Cornell University | <1 mi |
| TEE 3D RV Assessment for SAVR, Mini AVR, and TAVR | — | Thomas Jefferson University | <1 mi |
| Calculating Wall Shear Stress in Infant Pulmonary Veins | Phase 1 | Children's Hospital of Philadelphia | <1 mi |
| The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | Phase 3 | Johns Hopkins University | <1 mi |
| Neuroprognostication Bias: A Collaboration to Reduce the Impact of Self-fulfilling Prophecy in Cardiac ARrEst | — | Boston Medical Center | <1 mi |
| Evaluating the Relationship Between Skin Color and Pulse Oximeter Accuracy in Children | — | University of Pennsylvania | <1 mi |
| VIZ ACCESS HCM - Multi-Site Registry | — | Viz.ai, Inc. | <1 mi |
| A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM) | Phase 1 | Rocket Pharmaceuticals Inc. | <1 mi |
| North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | — | Columbia University | <1 mi |
| MASA Valve Early Feasibility Study | N/A | PECA Labs | <1 mi |
| Resuscitative TEE Collaborative Registry | — | University of Pennsylvania | <1 mi |
| An Early Feasibility Study of the HighLife 28mm Trans-Septal Transcatheter Mitral Valve Replacement System | N/A | HighLife SAS | <1 mi |
| Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure | Phase 4 | AstraZeneca | <1 mi |
| Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy | Phase 4 | Dennis M. McNamara, MD, MS | <1 mi |
| Inspiring New Science In Guiding Healthcare in Turner Syndrome Registry | — | University of Colorado, Denver | <1 mi |
| Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure | Phase 4 | Electrophysiology Research Foundation | <1 mi |
| Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS) | N/A | Innoventric LTD | <1 mi |
| Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure | N/A | Procyrion | <1 mi |
| COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction | N/A | Edwards Lifesciences | <1 mi |
| TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | Phase 3 | Alnylam Pharmaceuticals | <1 mi |
| International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry | — | SCAD Alliance | <1 mi |
| Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants | N/A | Nationwide Children's Hospital | <1 mi |
| MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) | Phase 3 | Intellia Therapeutics | <1 mi |
| A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease | Phase 2 | Rocket Pharmaceuticals Inc. | <1 mi |
| PARTNER 3 Trial - Aortic Valve-in-Valve | N/A | Edwards Lifesciences | <1 mi |
| Home-Based Exercise Program Using Mobile Technology After Left Ventricular Assist Device Implantation | N/A | University of Pennsylvania | <1 mi |
| Fontan Fitness Trial | N/A | Children's Hospital of Philadelphia | <1 mi |
| AI Powered Mapping Technology for Identifying Arrhythmias | — | Heart Rhythm Clinical and Research Solutions, LLC | <1 mi |
| Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM | Phase 1/2 | Tenaya Therapeutics | <1 mi |
| Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | Phase 3 | Eidos Therapeutics, a BridgeBio company | <1 mi |
| The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients | Phase 4 | University of Rochester | <1 mi |
| Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression | — | University of Pennsylvania | <1 mi |
| Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin | Phase 3 | AstraZeneca | <1 mi |
| Cord Clamping Among Neonates With Congenital Heart Disease | N/A | Carl Backes, MD | <1 mi |
| Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study | N/A | Vektor Medical | <1 mi |
| A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) | Phase 2 | Tectonic Therapeutic | <1 mi |
| The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR | N/A | Cardiac Dimensions, Inc. | <1 mi |
| EluPro Antibiotic-Eluting BioEnvelope Registry | — | Elutia Inc. | <1 mi |
| Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation | Early 1 | University of Pennsylvania | <1 mi |
| A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis | Phase 2 | Novartis Pharmaceuticals | <1 mi |
| Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual) | — | McMaster University | <1 mi |
| A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | Phase 3 | X4 Pharmaceuticals | <1 mi |
| Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery | Phase 4 | Thomas Jefferson University | <1 mi |
| Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study | N/A | Ancora Heart, Inc. | <1 mi |
| A Study of SGT-212 Gene Therapy in Friedreich's Ataxia | Phase 1 | Solid Biosciences Inc. | <1 mi |
| Characterization and Natural History of Williams Syndrome and Other Chromosome 7q11.23 Variants | — | University of Pennsylvania | <1 mi |
| CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting | — | Corcym S.r.l | <1 mi |
| CTSN Embolic Protection Trial | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| ViewFlex X ICE First-in-Human Study | — | Abbott Medical Devices | <1 mi |
| Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG | Phase 3 | Icahn School of Medicine at Mount Sinai | <1 mi |
| Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY) | N/A | Annetine Gelijns | <1 mi |
| Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients | Phase 2 | University of Pennsylvania | <1 mi |
| Abatacept in Immune Checkpoint Inhibitor Myocarditis | Phase 3 | Massachusetts General Hospital | <1 mi |
| Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment | — | Children's Oncology Group | <1 mi |
| His-Bundle Corrective Pacing in Heart Failure | N/A | University of Rochester | <1 mi |
| Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS) | N/A | Medtronic Cardiac Ablation Solutions | <1 mi |
| The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation. | — | Heart Rhythm Clinical and Research Solutions, LLC | <1 mi |
| Fibrosis and the Fontan | Phase 1/2 | Children's Hospital of Philadelphia | <1 mi |
| Randomized Assessment of TcMS for VT Storm | N/A | University of Pennsylvania | <1 mi |
| HeartShare: Combining Omics, Deep Phenotyping, and Electronic Health Records for Heart Failure Subtypes and Treatment Targets | — | Northwestern University | <1 mi |
| A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation | Phase 3 | Novo Nordisk A/S | <1 mi |
| Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT) | N/A | Varian, a Siemens Healthineers Company | <1 mi |
| Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) | Phase 2/3 | Merck Sharp & Dohme LLC | <1 mi |
| The Path to Optimal Black Maternal Heart Health: Comparing Two CVD Risk Reduction Interventions (Change of HEART) | N/A | Temple University | <1 mi |
| Prospective 4D CTA of BAV Competence | — | University of Pennsylvania | <1 mi |
| Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | Phase 3 | Cytokinetics | <1 mi |
| Outcomes and Health Care Resource Utilization in Pediatric Congenital Heart Disease Patients Undergoing Non-Cardiac Procedures | — | Boston Children's Hospital | <1 mi |
| The Fourth Left Atrial Appendage Occlusion Study | N/A | Hamilton Health Sciences Corporation | <1 mi |
| Valved Graft PMCF Study | — | Abbott Medical Devices | <1 mi |
| Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women | N/A | Weill Medical College of Cornell University | <1 mi |
| TVMR With the INNOVALVE System Trial - Early Feasibility Study | N/A | Edwards Lifesciences | <1 mi |
| ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™ | N/A | JenaValve Technology, Inc. | <1 mi |
| Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction | — | Northwestern University | <1 mi |
| Pivotal Study for the Cardiac Performance System (CPS) | — | Sensydia Corporation | <1 mi |
| A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF) | N/A | Biosense Webster, Inc. | <1 mi |
| Penn Medicine Healthy Heart | N/A | University of Pennsylvania | <1 mi |
| Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP) | N/A | University of Michigan | <1 mi |
| Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis | Phase 3 | Life Molecular Imaging GmbH | <1 mi |
| Clinical Study of the inQB8 TTVR System | N/A | inQB8 Medical Technologies, LLC | <1 mi |
| A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | Phase 3 | Teva Branded Pharmaceutical Products R&D, Inc. | <1 mi |
| SMART Implementation-Effectiveness Trial 2 | N/A | Children's Hospital of Philadelphia | <1 mi |
| Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma | Phase 2 | Sanofi | <1 mi |
| A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | Phase 3 | Teva Branded Pharmaceutical Products R&D LLC | <1 mi |
| Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | Phase 4 | Sanofi | <1 mi |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma | Phase 2 | Incyte Corporation | <1 mi |
| SMART Implementation-Effectiveness Trial 1 | N/A | Children's Hospital of Philadelphia | <1 mi |
| A Study to Evaluate Solriktug in Adult Participants With Asthma | Phase 2 | Uniquity One (UNI) | <1 mi |
| Psoriatic Arthritis D2P Screening | N/A | Jessica Walsh | <1 mi |
| Zimmer Biomet Shoulder Arthroplasty PMCF | N/A | Zimmer Biomet | <1 mi |
| AETOS Shoulder System | — | Smith & Nephew, Inc. | <1 mi |
| Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry | — | Duke University | <1 mi |
| Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients | Phase 3 | University of Pennsylvania | <1 mi |
| Clinical Outcomes Study of the Nexel Total Elbow | N/A | Zimmer Biomet | <1 mi |
| A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| Rehabilitation for Arthritis of The Knee: mainTaining Improvement for Veterans | Phase 3 | VA Office of Research and Development | <1 mi |
| Oral Nutritional Optimization in Total Joint Arthroplasty | N/A | NYU Langone Health | <1 mi |
| Aptis PRUJ Prosthesis for the Treatment of Patients With Proximal Radial Ulna Joint Disorders. | N/A | Aptis Medical | <1 mi |
| SMR Stemless Reverse Vs SMR Reverse Shoulder System | N/A | Limacorporate S.p.a | <1 mi |
| SPIROMICS Study of Early COPD Progression (SOURCE) | — | University of Massachusetts, Worcester | <1 mi |
| Feasibility of Semaglutide in Advanced Lung Disease | Phase 1/2 | University of Pennsylvania | <1 mi |
| Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD | Phase 2 | Johns Hopkins University | <1 mi |
| Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD | N/A | Nuvaira, Inc. | <1 mi |
| A Study to Evaluate Solrikitug in Participants With COPD (ZION) | Phase 2 | Uniquity One (UNI) | <1 mi |
| A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Hoffmann-La Roche | <1 mi |
| myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home | N/A | Temple University | <1 mi |
| Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease | N/A | University of Alabama at Birmingham | <1 mi |
| A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease | Phase 2 | AstraZeneca | <1 mi |
| An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema | N/A | Pulmonx Corporation | <1 mi |
| STRIVE Post-Market Registry Study | — | Olympus Corporation of the Americas | <1 mi |
| Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3 | N/A | Apreo Health, Inc. | <1 mi |
| Supporting Evidence-based Responses to Emotional Needs in Emphysema | N/A | University of Pennsylvania | <1 mi |
| Biological Effects of Quercetin in COPD Phase II | Phase 2 | Temple University | <1 mi |
| ACT With CF Self-Help Toolkit | N/A | Thomas Jefferson University | <1 mi |
| Postpartum Care in the NICU (PeliCaN) Transitions | N/A | University of Pennsylvania | <1 mi |
| A Study Comparing Music Therapy and Cognitive Behavioral Therapy for Anxiety in Cancer Survivors | Phase 4 | Memorial Sloan Kettering Cancer Center | <1 mi |
| SEEG-Guided DBS for OCD | N/A | Casey H. Halpern, M.D. | <1 mi |
| Foundational Programs to Combat Clinician Stress | N/A | Lancaster General Hospital | <1 mi |
| Brain Activity Changes After Cognitive Behavioral Therapy for Anxiety in Autistic Youth From High-Need Communities | N/A | Montclair State University | <1 mi |
| Decoding and Modulating Affective Brain States | N/A | University of Pennsylvania | <1 mi |
| Evaluation of the PACE/PACENET BHL Clinical Program | — | University of Pennsylvania | <1 mi |
| CRISOL Mente: A Multilevel Community Intervention to Reduce Mental Health Disparities Among Latinos | N/A | Drexel University | <1 mi |
| Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device | — | Gaize | <1 mi |
| Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging) | Phase 2 | Michael J. Fox Foundation for Parkinson's Research | <1 mi |
| Adaptive Neurostimulation to Restore Sleep in Parkinson's Disease (Aim 2) | N/A | University of Nebraska | <1 mi |
| A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) | Phase 2 | AskBio Inc | <1 mi |
| A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications | — | InSightec | <1 mi |
| PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort | — | Michael J. Fox Foundation for Parkinson's Research | <1 mi |
| Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503 | Early 1 | University of Pennsylvania | <1 mi |
| Parkinson's Foundation PD GENEration Genetic Registry | — | Parkinson's Foundation | <1 mi |
| A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease | Phase 2 | Neuron23 Inc. | <1 mi |
| Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis | Phase 4 | VA Office of Research and Development | <1 mi |
| Parkinson's Disease and Movement Disorders Clinical Database | — | University of Pennsylvania | <1 mi |
| RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus | Phase 1/2 | Cabaletta Bio | <1 mi |
| Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | Phase 4 | GlaxoSmithKline | <1 mi |
| Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus | — | University of Pennsylvania | <1 mi |
| A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants | — | Bristol-Myers Squibb | <1 mi |
| A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) | Phase 2 | Immunovant Sciences GmbH | <1 mi |
| A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | Phase 2/3 | Biogen | <1 mi |
| A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants | Phase 2 | Hoffmann-La Roche | <1 mi |
| A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| VIBRANT: VIB4920 for Active Lupus Nephritis | Phase 2 | National Institute of Allergy and Infectious Diseases (NIAID) | <1 mi |
| A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease | Phase 1 | Fate Therapeutics | <1 mi |
| CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus | Phase 1/2 | Children's Hospital of Philadelphia | <1 mi |
| An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants | Phase 3 | AstraZeneca | <1 mi |
| Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V | Phase 2 | Novartis Pharmaceuticals | <1 mi |
| A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus | Phase 3 | AstraZeneca | <1 mi |
| A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | Phase 3 | Viatris Innovation GmbH | <1 mi |
| Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases | Phase 2 | Stephan Grupp MD PhD | <1 mi |
| Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | Phase 3 | AbbVie | <1 mi |
| Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity | Phase 2 | Celgene | <1 mi |
| Obesity and Pediatric Multiple Sclerosis | — | University of Virginia | <1 mi |
| A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients | Phase 2 | Tiziana Life Sciences LTD | <1 mi |
| TSC Biosample Repository and Natural History Database | — | National Tuberous Sclerosis Association | <1 mi |
| Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis | Phase 4 | National Institute of Allergy and Infectious Diseases (NIAID) | <1 mi |
| Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) | Phase 3 | National Institute of Allergy and Infectious Diseases (NIAID) | <1 mi |
| AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy | Phase 1/2 | UniQure Biopharma B.V. | <1 mi |
| Study of COYA 302 for the Treatment of ALS | Phase 2 | Coya Therapeutics | <1 mi |
| AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis | Phase 1 | Amylyx Pharmaceuticals Inc. | <1 mi |
| Central Vein Sign in Multiple Sclerosis Extension Study | N/A | The Cleveland Clinic | <1 mi |
| Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | Phase 3 | Sanofi | <1 mi |
| Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis | Phase 3 | Sanofi | <1 mi |
| Safe and Explainable AI | — | Abramson Cancer Center at Penn Medicine | <1 mi |
| Prediction of Neoadjuvant Chemotherapy Response Using Contrast-Enhanced Ultrasound in Patients With Locally Advanced Breast Cancer | Phase 2/3 | Kibo Nam | <1 mi |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Virtual Mindful After Cancer (MAC) Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors | Phase 1 | Oregon State University | <1 mi |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | Phase 1/2 | 858 Therapeutics, Inc. | <1 mi |
| Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | Phase 2 | Dana-Farber Cancer Institute | <1 mi |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Phase 3 | Gilead Sciences | <1 mi |
| Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer | N/A | Thomas Jefferson University | <1 mi |
| EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients | — | Thomas Jefferson University | <1 mi |
| Study of INCB123667 in Subjects With Advanced Solid Tumors | Phase 1 | Incyte Corporation | <1 mi |
| Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer | N/A | Massachusetts General Hospital | <1 mi |
| CTNNA1 Familial Expansion Study | — | Abramson Cancer Center at Penn Medicine | <1 mi |
| The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study | Phase 3 | American Society of Clinical Oncology | <1 mi |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | Phase 3 | Hoffmann-La Roche | <1 mi |
| A Registry for People With T-cell Lymphoma | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| FES BPET-DBT in Newly Diagnosed Breast Cancer | Early 1 | Abramson Cancer Center at Penn Medicine | <1 mi |
| Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | Phase 2 | Dana-Farber Cancer Institute | <1 mi |
| ATEMPT 2.0: Adjuvant T-DM1 vs TH | Phase 2 | Dana-Farber Cancer Institute | <1 mi |
| A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors | Phase 1 | Normunity AccelCo, Inc. | <1 mi |
| The Cancer of the Pancreas Screening-5 CAPS5)Study | Phase 3 | Johns Hopkins University | <1 mi |
| Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | MOMA Therapeutics | <1 mi |
| ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer | Phase 2 | Abramson Cancer Center at Penn Medicine | <1 mi |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | Phase 3 | AstraZeneca | <1 mi |
| Prospective Breast Cancer Biospecimen Collection | — | Thomas Jefferson University | <1 mi |
| PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer | N/A | Abramson Cancer Center at Penn Medicine | <1 mi |
| Neoadjuvant Breast Cancer Time Restricted Eating | N/A | Thomas Jefferson University | <1 mi |
| A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer | Phase 2 | Puma Biotechnology, Inc. | <1 mi |
| A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors | Phase 1 | Totus Medicines | <1 mi |
| A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | Phase 1/2 | ORIC Pharmaceuticals | <1 mi |
| Study of AVZO-021 in Patients With Advanced Solid Tumors | Phase 1/2 | Avenzo Therapeutics, Inc. | <1 mi |
| Surviving Daily Life | — | Thomas Jefferson University | <1 mi |
| B.Brilliant Revelation Comparision Study | — | University of Pennsylvania | <1 mi |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Phase 2 | QuantumLeap Healthcare Collaborative | <1 mi |
| QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer | — | Abramson Cancer Center at Penn Medicine | <1 mi |
| [18F] F-GLN by PET/CT in Breast Cancer | Phase 1 | Abramson Cancer Center at Penn Medicine | <1 mi |
| Role of the Immune Environment in Response to Therapy in Breast Cancer | — | Abramson Cancer Center at Penn Medicine | <1 mi |
| Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | Phase 3 | Celcuity Inc | <1 mi |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | Phase 1/2 | Hoffmann-La Roche | <1 mi |
| Study of LP-184 in Patients With Advanced Solid Tumors | Phase 1/2 | Lantern Pharma Inc. | <1 mi |
| Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer | Phase 2 | Abramson Cancer Center at Penn Medicine | <1 mi |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | Early 1 | Presage Biosciences | <1 mi |
| A Study of LY4337713 in Participants With FAP-Positive Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| African Cancer Genome: GMD | — | Fox Chase Cancer Center | <1 mi |
| Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer | — | Sir Mortimer B. Davis - Jewish General Hospital | <1 mi |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | Phase 1/2 | Hoffmann-La Roche | <1 mi |
| Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts | N/A | American College of Radiology | <1 mi |
| A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | Phase 3 | Jazz Pharmaceuticals | <1 mi |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | Phase 2 | Laura Huppert, MD, BA | <1 mi |
| ETHAN - ET for Male BC | Phase 2 | Jose Pablo Leone | <1 mi |
| [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer | Phase 1 | Novartis Pharmaceuticals | <1 mi |
| Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry) | — | University of California, San Francisco | <1 mi |
| A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | Phase 1 | IDEAYA Biosciences | <1 mi |
| Empathic Communication Skills (ECS) Training | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Registry for People With Lung Cancer | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | Phase 1/2 | IDEAYA Biosciences | <1 mi |
| FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | Phase 1 | Fate Therapeutics | <1 mi |
| A Long-term Extension Study of PCI-32765 (Ibrutinib) | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC | Phase 2 | Fox Chase Cancer Center | <1 mi |
| Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry | — | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | <1 mi |
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | <1 mi |
| A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS | Phase 3 | AstraZeneca | <1 mi |
| First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations | Phase 1/2 | Pierre Fabre Medicament | <1 mi |
| A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) | Phase 1/2 | Daiichi Sankyo | <1 mi |
| Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC | Phase 1/2 | VA Office of Research and Development | <1 mi |
| Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors | Phase 1 | AstraZeneca | <1 mi |
| LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC | Phase 3 | NovoCure GmbH | <1 mi |
| Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy | N/A | VA Office of Research and Development | <1 mi |
| Safety and Durability of Sirolimus for Treatment of LAM | — | University of Cincinnati | <1 mi |
| A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 3 | AstraZeneca | <1 mi |
| Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors | Phase 1 | InSilico Medicine Hong Kong Limited | <1 mi |
| Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Phase 1 | Incyte Corporation | <1 mi |
| Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | Phase 1/2 | Tasca Therapeutics | <1 mi |
| A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | Phase 1/2 | Novartis Pharmaceuticals | <1 mi |
| A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | Phase 1/2 | Eutilex | <1 mi |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | — | Guardant Health, Inc. | <1 mi |
| A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| Telehealth Collaborative Care Model (CoCM) in Lung Cancer | N/A | Abramson Cancer Center at Penn Medicine | <1 mi |
| A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations | Phase 1/2 | Daiichi Sankyo | <1 mi |
| CT-95 in Advanced Cancers Associated With Mesothelin Expression | Phase 1 | Context Therapeutics Inc. | <1 mi |
| A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors | Phase 1/2 | Frontier Medicines Corporation | <1 mi |
| Temple Health Chest Initiative (THCI 2.0) | — | Temple University | <1 mi |
| Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab | Phase 1/2 | Linnaeus Therapeutics, Inc. | <1 mi |
| A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations | Phase 1/2 | BlossomHill Therapeutics | <1 mi |
| Integrating Telehealth to Advance Lung Cancer Screening | N/A | Abramson Cancer Center at Penn Medicine | <1 mi |
| Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | Phase 2 | Fox Chase Cancer Center | <1 mi |
| Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer | Phase 2 | BicycleTx Limited | <1 mi |
| A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Johnson & Johnson Enterprise Innovation Inc. | <1 mi |
| Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | Phase 1 | Janux Therapeutics | <1 mi |
| A Phase 1 Study of LNCB74 in Advanced Solid Tumors | Phase 1 | NextCure, Inc. | <1 mi |
| A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | Phase 1/2 | Verastem, Inc. | <1 mi |
| A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors | Phase 1 | Conjupro Biotherapeutics, Inc. | <1 mi |
| Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer | Phase 1 | Abramson Cancer Center at Penn Medicine | <1 mi |
| SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma | Phase 1 | Verismo Therapeutics | <1 mi |
| Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors | Phase 1 | Calico Life Sciences LLC | <1 mi |
| The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer | N/A | Thomas Jefferson University | <1 mi |
| Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking | N/A | Ronald Myers | <1 mi |
| Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy | Phase 1/2 | Abramson Cancer Center at Penn Medicine | <1 mi |
| ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy | Phase 2 | Abramson Cancer Center at Penn Medicine | <1 mi |
| AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors | Phase 1 | Amgen | <1 mi |
| MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma | Phase 3 | AstraZeneca | <1 mi |
| A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | Phase 1/2 | Cogent Biosciences, Inc. | <1 mi |
| Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance | Phase 2 | Abramson Cancer Center at Penn Medicine | <1 mi |
| A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer | Phase 1/2 | Janssen Research & Development, LLC | <1 mi |
| A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | Phase 2 | Lantern Pharma Inc. | <1 mi |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | Phase 1/2 | Eli Lilly and Company | <1 mi |
| Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies | Phase 1 | TopAlliance Biosciences | <1 mi |
| JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer | Phase 3 | University of Texas Southwestern Medical Center | <1 mi |
| Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | Phase 1 | EvolveImmune United, Inc | <1 mi |
| RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | Phase 2 | Reunion Neuroscience Inc | <1 mi |
| A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation | Phase 1 | Clasp Therapeutics, Inc. | <1 mi |
| Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES | N/A | Abramson Cancer Center at Penn Medicine | <1 mi |
| MOv19-BBz CAR T Cells in FRa+ Cancers | Phase 1 | University of Pennsylvania | <1 mi |
| AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) | Phase 1/2 | Avenzo Therapeutics, Inc. | <1 mi |
| First in Human Study of AZD9592 in Solid Tumors | Phase 1 | AstraZeneca | <1 mi |
| A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) | Phase 1 | Amgen | <1 mi |
| KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01) | — | Merck Sharp & Dohme LLC | <1 mi |
| Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer | Phase 2 | Integro Theranostics | <1 mi |
| A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer | Phase 1 | Johnson & Johnson Enterprise Innovation Inc. | <1 mi |
| AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). | Phase 1 | Amgen | <1 mi |
| A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | NiKang Therapeutics, Inc. | <1 mi |
| PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial | N/A | Thomas Jefferson University | <1 mi |
| Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM) | Phase 1 | Abramson Cancer Center at Penn Medicine | <1 mi |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | Phase 1/2 | Turning Point Therapeutics, Inc. | <1 mi |
| Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study | N/A | AIDS Malignancy Consortium | <1 mi |
| A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease | N/A | Indiana University | <1 mi |
| TReatment for ImmUne Mediated PathopHysiology | Phase 2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | <1 mi |
| A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition | Phase 2 | Regeneron Pharmaceuticals | <1 mi |
| Drug-Induced Liver Injury (DILI) Network Retrospective | — | Duke University | <1 mi |
| Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | — | European Foundation for Study of Chronic Liver Failure | <1 mi |
| FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study | Phase 2 | Intercept Pharmaceuticals | <1 mi |
| Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal | Phase 3 | Thomas Jefferson University | <1 mi |
| Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics | Phase 1 | PharmaIN | <1 mi |
| Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | Phase 3 | Gilead Sciences | <1 mi |
| A Prospective Database of Infants With Cholestasis | — | Arbor Research Collaborative for Health | <1 mi |
| Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | Phase 3 | Mirum Pharmaceuticals, Inc. | <1 mi |
| A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Condition | — | Astellas Gene Therapies | <1 mi |
| Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma | Phase 2 | Abramson Cancer Center at Penn Medicine | <1 mi |
| Primary Sclerosing Cholangitis in Children | — | Arbor Research Collaborative for Health | <1 mi |
| ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) | — | Alnylam Pharmaceuticals | <1 mi |
| Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD) | Phase 2 | Shionogi | <1 mi |
| Liver Disease in Urea Cycle Disorders | — | Baylor College of Medicine | <1 mi |
| A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) | — | Target PharmaSolutions, Inc. | <1 mi |
| Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US) | — | Mirum Pharmaceuticals, Inc. | <1 mi |
| Cholate Clearance in Fontan and Heart Failure | — | HepQuant, LLC | <1 mi |
| Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease | N/A | University of Pennsylvania | <1 mi |
| DILIN - Prospective Study | — | Duke University | <1 mi |
| Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant | N/A | University of Pennsylvania | <1 mi |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease | Phase 2 | GlaxoSmithKline | <1 mi |
| The Myelin Disorders Biorepository Project | — | Children's Hospital of Philadelphia | <1 mi |
| Genetic Collection Protocol | — | Arbor Research Collaborative for Health | <1 mi |
| Longitudinal Study of the Porphyrias | — | Icahn School of Medicine at Mount Sinai | <1 mi |
| Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein | Phase 3 | Takeda | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH | Phase 3 | 89bio, Inc. | <1 mi |
| Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema | Phase 2 | Sanofi | <1 mi |
| SHAPE of Portal Hypertension in Children | Phase 2 | Thomas Jefferson University | <1 mi |
| A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | Phase 2 | AstraZeneca | <1 mi |
| Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| Observational Study Protocol: LIVER-R | — | AstraZeneca | <1 mi |
| Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors | Phase 2 | SWOG Cancer Research Network | <1 mi |
| National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer | — | National Cancer Institute (NCI) | <1 mi |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) | Phase 1 | AbbVie | <1 mi |
| SBRT With Atezo/Bev for HCC | Phase 1 | Abramson Cancer Center at Penn Medicine | <1 mi |
| Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer | Phase 1/2 | Teclison Ltd. | <1 mi |
| Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors | Phase 2 | john eisenbrey | <1 mi |
| An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery | — | Bayer | <1 mi |
| National Liver Cancer Screening Trial | Phase 4 | University of Texas Southwestern Medical Center | <1 mi |
| A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis | Phase 2 | Genentech, Inc. | <1 mi |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Phase 1/2 | Children's Oncology Group | <1 mi |
| Tebentafusp-tebn With LDT in Metastatic UM | Phase 1/2 | Thomas Jefferson University | <1 mi |
| Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients | — | University of California, San Diego | <1 mi |
| CapTemY90 for Grade 2/3 NET Liver Metastases | Phase 2 | Abramson Cancer Center at Penn Medicine | <1 mi |
| A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | <1 mi |
| Y-90 Treatment Response Using Transarterial Radioembolization | Phase 2 | Thomas Jefferson University | <1 mi |
| DESTINY-PANTUMOUR04 | — | AstraZeneca | <1 mi |
| Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | Phase 2 | Replimune Inc. | <1 mi |
| A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy | Phase 3 | Pierre Fabre Medicament | <1 mi |
| Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | Phase 3 | Crinetics Pharmaceuticals Inc. | <1 mi |
| Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years | Phase 4 | Guerbet | <1 mi |
| Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI | N/A | VA Office of Research and Development | <1 mi |
| Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial | Phase 2 | NRG Oncology | 3 mi |
| Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial | Phase 3 | NRG Oncology | 3 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | Phase 3 | AstraZeneca | 3 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC | Phase 3 | AstraZeneca | 3 mi |
| Product Surveillance Registry | — | Medtronic | 3 mi |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Phase 3 | Stemline Therapeutics, Inc. | 3 mi |
| Single Fraction or Multi-fraction Palliative Radiation Therapy for the Improvement of Quality of Life in Patients With Metastatic Gynecologic Cancers | Phase 2 | M.D. Anderson Cancer Center | 3 mi |
| Effects of Oncological Treatment During Pregnancy on Mother and Child | — | University Hospital, Gasthuisberg | 3 mi |
| DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) | Phase 2 | Diakonos Oncology Corporation | 3 mi |
| Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma | Phase 2 | M.D. Anderson Cancer Center | 3 mi |
| Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study | — | M.D. Anderson Cancer Center | 3 mi |
| Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | Phase 3 | RenovoRx | 3 mi |
| Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | Phase 3 | AstraZeneca | 3 mi |
| Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. | Phase 3 | Iovance Biotherapeutics, Inc. | 3 mi |
| The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer | Phase 2 | M.D. Anderson Cancer Center | 3 mi |
| Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer | Phase 4 | Pfizer | 3 mi |
| Customized 3D Printed Oral Stents During Head and Neck Radiotherapy | Phase 2 | M.D. Anderson Cancer Center | 3 mi |
| SPYRAL GEMINI Pilot Study | N/A | Medtronic Vascular | 3 mi |
| Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes | N/A | Endogenex, Inc. | 3 mi |
| Prevail Global Study | N/A | Medtronic Vascular | 3 mi |
| Lymphatic System Stimulation in Heart Failure | N/A | Rutgers, The State University of New Jersey | 3 mi |
| Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement | N/A | University of British Columbia | 3 mi |
| Standardized Yoga & Meditation Program for Stress Reduction for Adolescents With Irritable Bowel Syndrome | N/A | The Cooper Health System | 3 mi |
| Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors | N/A | NRG Oncology | 3 mi |
| Maternal Cancer Diagnosis and Treatment During Pregnancy:a Database for Maternal, Fetal, and Neonatal Outcomes | — | The Cooper Health System | 3 mi |
| Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) | Phase 2 | Merck Sharp & Dohme LLC | 3 mi |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Phase 1/2 | Eisai Inc. | 3 mi |
| Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy | N/A | The Cooper Health System | 3 mi |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | Phase 2 | Iovance Biotherapeutics, Inc. | 3 mi |
| Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | Phase 1/2 | Genmab | 3 mi |
| Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy | N/A | The Cooper Health System | 3 mi |
| A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Janssen Research & Development, LLC | 5 mi |
| A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) | Phase 2 | Merck Sharp & Dohme LLC | 5 mi |
| Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer | Phase 3 | Bayer | 5 mi |
| Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management | Phase 3 | MidLantic Urology | 5 mi |
| A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | Phase 1 | Astellas Pharma Global Development, Inc. | 5 mi |
| A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer | Phase 3 | Janssen Research & Development, LLC | 5 mi |
| Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase 2 | Tyra Biosciences, Inc | 5 mi |
| A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 3 | Janssen Research & Development, LLC | 5 mi |
| Study of ORIC-944 in Patients With Metastatic Prostate Cancer | Phase 1 | ORIC Pharmaceuticals | 5 mi |
| Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients | Phase 2 | Theralase® Technologies Inc. | 5 mi |
| A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer | Phase 3 | Janssen Research & Development, LLC | 5 mi |
| Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T | Phase 2 | Dendreon | 5 mi |
| The HEARTFELT Study | N/A | Heartfelt Technologies | 5 mi |
| ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG | Phase 1/2 | ImmunityBio, Inc. | 5 mi |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | Phase 3 | National Cancer Institute (NCI) | 7 mi |
| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | Phase 3 | SWOG Cancer Research Network | 7 mi |
| A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) | Phase 3 | Pfizer | 7 mi |
| The CONFORM Pivotal Trial | N/A | Conformal Medical, Inc | 7 mi |
| A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer | Phase 1/2 | Pfizer | 7 mi |
| ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System | N/A | Edwards Lifesciences | 7 mi |
| Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer | Phase 3 | GOG Foundation | 7 mi |
| A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC) | Phase 2 | SCRI Development Innovations, LLC | 7 mi |
| Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations | Phase 2 | Boehringer Ingelheim | 7 mi |
| Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer | Phase 3 | NRG Oncology | 7 mi |
| Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections | N/A | Medtronic - MITG | 7 mi |
| A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | Phase 3 | BeiGene | 7 mi |
| PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR | N/A | Edwards Lifesciences | 7 mi |
| REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE | — | Medtronic Cardiovascular | 7 mi |
| LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 | Phase 3 | Tenax Therapeutics, Inc. | 7 mi |
| Trisol System EFS Study | N/A | Trisol Medical | 7 mi |
| Medtronic Terminate AF Study | N/A | Medtronic Cardiac Surgery | 7 mi |
| Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023) | Phase 2 | Merck Sharp & Dohme LLC | 7 mi |
| Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. | N/A | Medtronic Cardiovascular | 7 mi |
| Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma | Phase 4 | Regeneron Pharmaceuticals | 7 mi |
| DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment | Phase 2 | QuantumLeap Healthcare Collaborative | 7 mi |
| Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | Phase 3 | Novartis Pharmaceuticals | 7 mi |
| A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) | — | TG Therapeutics, Inc. | 7 mi |
| Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults | Phase 2 | Autobahn Therapeutics, Inc. | 7 mi |
| A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder | Phase 2 | Sirtsei Pharmaceuticals, Inc. | 7 mi |
| A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms | Phase 4 | Axsome Therapeutics, Inc. | 7 mi |
| Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol | Phase 3 | Axsome Therapeutics, Inc. | 7 mi |
| A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) | Phase 3 | Xenon Pharmaceuticals Inc. | 7 mi |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | Phase 3 | Xenon Pharmaceuticals Inc. | 7 mi |
| Multiple Sclerosis Implementation Network (Registry) | — | The University of Texas Health Science Center, Houston | 7 mi |
| A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment | — | Ipsen | 7 mi |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | Phase 4 | Duke University | 7 mi |
| Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | Phase 2 | National Cancer Institute (NCI) | 8 mi |
| Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial | Phase 3 | SWOG Cancer Research Network | 8 mi |
| Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers | Phase 2 | NRG Oncology | 8 mi |
| Unlocking Movement Potential: Enhancing Parkinson's Disease Treatment With Robotic EksoSkeleton | N/A | Albert Einstein Healthcare Network | 9 mi |
| MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles | — | Agendia | 10 mi |
| A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | Phase 3 | Zai Lab (Shanghai) Co., Ltd. | 10 mi |
| A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | Phase 3 | DualityBio Inc. | 10 mi |
| Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC | Phase 1/2 | Xencor, Inc. | 10 mi |
| A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | Phase 3 | Merck Sharp & Dohme LLC | 10 mi |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis | Phase 3 | Boehringer Ingelheim | 11 mi |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Phase 3 | Boehringer Ingelheim | 11 mi |
| Screening and Nutrition for Patients With Diabetes: A Pilot Study | N/A | Villanova University | 11 mi |
| A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD | Phase 3 | Annovis Bio Inc. | 12 mi |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | 12 mi |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | 12 mi |
| A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease | Phase 2 | Janssen Pharmaceutica N.V., Belgium | 12 mi |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) | Phase 3 | Bristol-Myers Squibb | 12 mi |
| A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Phase 3 | Hoffmann-La Roche | 12 mi |
| A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) | Phase 2 | Merck Sharp & Dohme LLC | 12 mi |
| Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies | Phase 3 | Hoffmann-La Roche | 12 mi |
| Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight | Phase 3 | Eli Lilly and Company | 12 mi |
| A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder | Phase 2 | VistaGen Therapeutics, Inc. | 12 mi |
| ACP-204 in Adults With Alzheimer's Disease Psychosis | Phase 2/3 | ACADIA Pharmaceuticals Inc. | 12 mi |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease | Phase 3 | Bristol-Myers Squibb | 12 mi |
| Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure | N/A | Abbott Medical Devices | 12 mi |
| Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 2 | Bristol-Myers Squibb | 12 mi |
| Ultrafiltration Versus IV Diuretics in Worsening Heart Failure | N/A | Nuwellis, Inc. | 12 mi |
| A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy | Phase 2 | Novo Nordisk A/S | 12 mi |
| A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | Phase 3 | Amgen | 12 mi |
| A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression | Phase 2 | Draig Therapeutics Ltd | 12 mi |
| A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD | Phase 3 | Lipocine Inc. | 12 mi |
| Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder | Phase 3 | Vanda Pharmaceuticals | 12 mi |
| Study of ALTO-300 in MDD | Phase 2 | Alto Neuroscience | 12 mi |
| Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder | Phase 2 | Intra-Cellular Therapies, Inc. | 12 mi |
| Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder | Phase 2 | Intra-Cellular Therapies, Inc. | 12 mi |
| Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy | — | Averitas Pharma, Inc. | 13 mi |
| Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | Phase 3 | AbbVie | 14 mi |
| A Study of Intra-operative Imaging in Women With Ovarian Cancer | Phase 3 | Memorial Sloan Kettering Cancer Center | 14 mi |
| A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease | Phase 2 | Novartis Pharmaceuticals | 14 mi |
| A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) | Phase 2 | Merck Sharp & Dohme LLC | 14 mi |
| A Study of Buntanetap in Participants With PD | Phase 2/3 | Annovis Bio Inc. | 14 mi |
| The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal | Phase 3 | The Cooper Health System | 14 mi |
| ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response | Phase 2 | ACADIA Pharmaceuticals Inc. | 14 mi |
| A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) | Phase 1 | Eli Lilly and Company | 14 mi |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | Phase 3 | Viking Therapeutics, Inc. | 14 mi |
| A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events | N/A | Cleerly, Inc. | 14 mi |
| Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System | N/A | Boston Scientific Corporation | 14 mi |
| Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure | — | Impulse Dynamics | 14 mi |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | Phase 3 | Amgen | 14 mi |
| A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease | Phase 3 | Hoffmann-La Roche | 14 mi |
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | — | Alliance for Clinical Trials in Oncology | 15 mi |
| Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | Phase 2 | SCRI Development Innovations, LLC | 15 mi |
| A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) | Phase 2 | Merck Sharp & Dohme LLC | 16 mi |
| Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) | Phase 3 | Anthos Therapeutics, Inc. | 16 mi |
| A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Phase 2 | Jazz Pharmaceuticals | 16 mi |
| Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder | Phase 3 | Neumora Therapeutics, Inc. | 17 mi |
| Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY) | Phase 2 | Autobahn Therapeutics, Inc. | 17 mi |
| BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S | N/A | Biotronik, Inc. | 18 mi |
| A Prospective Registry to Enable Collection of Standardized Routine Care Oncology Patient Data | — | N-Power Medicine | 18 mi |
| Molecular Genetics Studies of Cancer Patients and Their Relatives | — | City of Hope Medical Center | 18 mi |
| Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer | — | N-Power Medicine | 18 mi |
| Vitaccess Real MG Registry | — | Vitaccess Ltd | 19 mi |
| Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease) | Phase 3 | Endo Pharmaceuticals | 19 mi |
| Retrospective Analyses of TrakStar Database | — | Neuronetics | 19 mi |
| Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments | — | Neuronetics | 19 mi |
| Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | Phase 3 | Karyopharm Therapeutics Inc | 20 mi |
| Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays | N/A | Alliance for Clinical Trials in Oncology | 23 mi |
| Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment | Phase 3 | University of Rochester NCORP Research Base | 23 mi |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | Phase 3 | SWOG Cancer Research Network | 23 mi |
| Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula | Phase 3 | SWOG Cancer Research Network | 23 mi |
| Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body | Phase 3 | SWOG Cancer Research Network | 23 mi |
| Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors | Phase 3 | SWOG Cancer Research Network | 23 mi |
| Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects | — | Alliance for Clinical Trials in Oncology | 23 mi |
| Mobile Health for Adherence in Breast Cancer Patients | N/A | ECOG-ACRIN Cancer Research Group | 23 mi |
| Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | 23 mi |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study | Phase 3 | NRG Oncology | 23 mi |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer | Phase 3 | NRG Oncology | 23 mi |
| Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial | Phase 2 | National Cancer Institute (NCI) | 23 mi |
| Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study | Phase 3 | Alliance for Clinical Trials in Oncology | 23 mi |
| Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer | Phase 3 | Canadian Cancer Trials Group | 23 mi |
| A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Phase 3 | Eli Lilly and Company | 24 mi |
| Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease | Phase 2 | Regeneron Pharmaceuticals | 24 mi |
| A Study of Dotinurad Versus Allopurinol in Participants With Gout | Phase 3 | Crystalys Therapeutics | 24 mi |
| Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | Phase 2 | AbbVie | 24 mi |
| E-Mindfulness Approaches for Living After Breast Cancer | Phase 3 | NRG Oncology | 24 mi |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis | Phase 2/3 | CSL Behring | 25 mi |
| RA-PRO PRAGMATIC TRIAL | Phase 3 | University of Alabama at Birmingham | 25 mi |
| An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study | — | University of Rochester NCORP Research Base | 25 mi |
| LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia | — | University of Rochester | 25 mi |
| Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer | — | Wake Forest University Health Sciences | 25 mi |
| Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients | Phase 3 | Alliance for Clinical Trials in Oncology | 25 mi |
| Collection and Storage of Tissue and Blood Samples From Patients With Cancer | — | National Cancer Institute LAO | 25 mi |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma | Phase 1/2 | Bristol-Myers Squibb | 25 mi |
| Simple Bone Cysts in Kids | Phase 3 | The Hospital for Sick Children | 25 mi |
| The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL | Phase 2 | Pediatric Transplantation & Cellular Therapy Consortium | 25 mi |
| Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation | — | BioDelivery Sciences International | 25 mi |
| Testing eSCCIP: An eHealth Psychosocial Intervention for English and Spanish Speaking Parents of Children With Cancer | N/A | Nemours Children's Clinic | 25 mi |
| Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer | N/A | Alliance for Clinical Trials in Oncology | 25 mi |
| Transdisciplinary Care for Young Adults With Type 1 Diabetes | N/A | Nemours Children's Clinic | 25 mi |
| A Basket Study of Vosoritide in Children With Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment | Phase 2 | BioMarin Pharmaceutical | 25 mi |
| GRANITE: Airsupra Effectiveness in the Real World | — | AstraZeneca | 25 mi |
| Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | Phase 3 | AstraZeneca | 25 mi |
| Tezspire Cardiac Events PASS | — | AstraZeneca | 25 mi |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | — | Duke University | 25 mi |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) | Phase 3 | AstraZeneca | 25 mi |
| Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer | Phase 2 | Faeth Therapeutics | 25 mi |
| SPHERE Per-AF Post-Approval Study | — | Medtronic Cardiac Ablation Solutions | 25 mi |
| PULSED AF Post-Approval Study | — | Medtronic Cardiac Ablation Solutions | 25 mi |
| A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | Phase 3 | Boehringer Ingelheim | 26 mi |
| A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes | Phase 2 | Eli Lilly and Company | 29 mi |
| Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy | — | Stanford University | 29 mi |
| PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm | N/A | Kardion Inc | 31 mi |
| Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial | N/A | Sonavex, Inc. | 33 mi |
| Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | Phase 3 | Merck Sharp & Dohme LLC | 33 mi |
| Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program | Phase 3 | Alliance for Clinical Trials in Oncology | 33 mi |
| Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps | N/A | NRG Oncology | 35 mi |
| Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study | — | Wake Forest University Health Sciences | 36 mi |
| Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics | — | Wake Forest University Health Sciences | 36 mi |
| Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | Phase 3 | AstraZeneca | 36 mi |
| Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial | Phase 3 | University of Rochester | 36 mi |
| Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) | Phase 2/3 | BicycleTx Limited | 36 mi |
| A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma | Phase 2 | AstraZeneca | 36 mi |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | Phase 3 | Janssen Research & Development, LLC | 36 mi |
| A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 1 | AbbVie | 36 mi |
| A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | Phase 1/2 | Sanofi | 36 mi |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | Phase 3 | Genmab | 36 mi |
| Study of SGR-1505 in Mature B-Cell Neoplasms | Phase 1 | Schrödinger, Inc. | 36 mi |
| INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC | Phase 2/3 | Inhibrx Biosciences, Inc | 36 mi |
| Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma | Phase 3 | Alliance for Clinical Trials in Oncology | 36 mi |
| Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Nerviano Medical Sciences | 36 mi |
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC | Phase 2/3 | Bicara Therapeutics | 36 mi |
| Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors | Phase 1 | Riboscience, LLC. | 36 mi |
| Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma | Phase 2 | SCRI Development Innovations, LLC | 36 mi |
| Vitamin D for Prostate Endocrine Therapy | Phase 3 | University of Rochester | 36 mi |
| Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial | Phase 2 | Alliance for Clinical Trials in Oncology | 36 mi |
| Nested Pilot Study Comparing Two Treatments to Reduce Type 2 Diabetes Risk in At-Risk Delawareans | N/A | University of Delaware | 36 mi |
| Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease | Phase 3 | Prokidney | 36 mi |
| Evaluating the Effectiveness of a Food is Medicine Community Health Worker Program for Pregnant Women | N/A | Christiana Care Health Services | 36 mi |
| Linking Affective Dynamics in Response to Daily Stress to Peripheral Vascular Function in Working Age Adults | N/A | University of Delaware | 36 mi |
| Positive Processes and Transition to Health (PATH) | N/A | Case Western Reserve University | 36 mi |
| Promoting Independence With Compensatory Cognitive Rehabilitation | N/A | University of Delaware | 36 mi |
| Left Ventricular Structural Predictors of Sudden Cardiac Death | — | Johns Hopkins University | 36 mi |
| University of Delaware Parkinson's Disease Registry | — | University of Delaware | 36 mi |
| Light Therapy Intervention in Individuals With Parkinson's Disease | N/A | University of Delaware | 36 mi |
| Online Motor Control in People With Parkinson's Disease | N/A | University of Delaware | 36 mi |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | Phase 3 | Olema Pharmaceuticals, Inc. | 36 mi |
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | Phase 3 | Relay Therapeutics, Inc. | 36 mi |
| A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | Phase 3 | Merck Sharp & Dohme LLC | 36 mi |
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | Phase 1 | Tizona Therapeutics, Inc | 36 mi |
| Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study | Phase 2 | SWOG Cancer Research Network | 36 mi |
| A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) | Phase 3 | Bristol-Myers Squibb | 36 mi |
| Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment | Phase 1 | Gilead Sciences | 36 mi |
| A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome | Phase 3 | NewAmsterdam Pharma | 37 mi |
| To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications | Phase 3 | Cerevance | 37 mi |
| Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 | ARTBIO Inc. | 38 mi |
| Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer | Phase 3 | Curium US LLC | 38 mi |
| "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" | Phase 3 | Cybin IRL Limited | 38 mi |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) | Phase 3 | Bristol-Myers Squibb | 38 mi |
| Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder | Phase 3 | Vanda Pharmaceuticals | 38 mi |
| A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) | Phase 3 | Definium Therapeutics US, Inc. | 38 mi |
| A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer | Phase 1 | Radionetics Oncology | 38 mi |
| Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors | Phase 1 | Radiopharm Theranostics, Ltd | 38 mi |
| Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face | Phase 4 | Psoriasis Treatment Center of Central New Jersey | 40 mi |
| A Pilot Trial of "Just ASK™" to Increase Discussions About Breast Cancer Clinical Trials | N/A | University of Pennsylvania | 40 mi |
| A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia | Phase 2 | Janssen Research & Development, LLC | 42 mi |
| A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD | N/A | Cleerly, Inc. | 42 mi |
| Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. | Phase 3 | BriaCell Therapeutics Corporation | 42 mi |
| Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib | Phase 2 | Janssen Research & Development, LLC | 42 mi |
| MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels | N/A | Concept Medical Inc. | 45 mi |
| MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions | N/A | Concept Medical Inc. | 45 mi |
| A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | Phase 3 | Boehringer Ingelheim | 46 mi |
| Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | Phase 3 | BioNTech SE | 46 mi |
| A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Hoffmann-La Roche | 48 mi |
| Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer | Phase 3 | National Cancer Institute (NCI) | 48 mi |
| Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | Phase 2 | SWOG Cancer Research Network | 48 mi |
| Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors | — | ECOG-ACRIN Cancer Research Group | 48 mi |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | Phase 2 | National Cancer Institute (NCI) | 48 mi |
| Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations | Phase 2 | Alliance for Clinical Trials in Oncology | 48 mi |
| Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment | Phase 3 | SWOG Cancer Research Network | 48 mi |
| Heart Attack Research Program- Imaging Study | — | NYU Langone Health | 48 mi |
| Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) | Phase 3 | Daiichi Sankyo | 48 mi |
| Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial | Phase 3 | M.D. Anderson Cancer Center | 48 mi |
| Women's Heart Attack Research Program: Stress Ancillary Study | N/A | NYU Langone Health | 48 mi |
| A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) | — | Bristol-Myers Squibb | 48 mi |
| ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors | Phase 3 | OncoC4, Inc. | 48 mi |
| A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | Phase 3 | Merck Sharp & Dohme LLC | 48 mi |
| St. Joseph's HPV Self-sampling: Offering a Self-sampling Option in Clinic | N/A | Milton S. Hershey Medical Center | 48 mi |
| A Fruit and Vegetable Prescription Program | N/A | Milton S. Hershey Medical Center | 48 mi |
| Diabetes Clinical Decision Support | N/A | Milton S. Hershey Medical Center | 48 mi |
| Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | 48 mi |
| Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | 48 mi |
| Genomic Profiling in Cancer Patients | — | Memorial Sloan Kettering Cancer Center | 48 mi |
| Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia | — | Memorial Sloan Kettering Cancer Center | 48 mi |
| Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease | — | Memorial Sloan Kettering Cancer Center | 48 mi |
| Pembrolizumab, Olaparib, and Temozolomide for People With Glioma | Phase 2 | Memorial Sloan Kettering Cancer Center | 48 mi |
| Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors | Phase 2 | Memorial Sloan Kettering Cancer Center | 48 mi |
| A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 3 | Celgene | 48 mi |
| Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) | — | GT Medical Technologies, Inc. | 48 mi |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2/3 | Bristol-Myers Squibb | 48 mi |
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Kura Oncology, Inc. | 48 mi |
| Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone | N/A | Capsicure, LLC | 48 mi |
| Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder | Phase 2 | Syndeio Biosciences, Inc | 48 mi |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | Phase 3 | Xenon Pharmaceuticals Inc. | 48 mi |
| A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 48 mi |
| GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study | N/A | W.L.Gore & Associates | 48 mi |
| Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study | N/A | Stanford University | 48 mi |
| Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine | Phase 2 | State University of New York - Upstate Medical University | 48 mi |
| A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | 48 mi |
| A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Bristol-Myers Squibb | 48 mi |
| Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease | Phase 2 | Memorial Sloan Kettering Cancer Center | 48 mi |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | Phase 2/3 | Mirati Therapeutics Inc. | 48 mi |
| Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) | Phase 3 | Amgen | 48 mi |
| A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Memorial Sloan Kettering Cancer Center | 48 mi |
| Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study) | — | HistoSonics, Inc. | 48 mi |
| Myriad™ Augmented Soft Tissue Reconstruction Registry | — | Aroa Biosurgery Limited | 49 mi |
| A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) | Phase 3 | BeOne Medicines | 49 mi |
| DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 49 mi |
| A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer | Phase 3 | National Cancer Institute (NCI) | 49 mi |
| Impact of a Diabetes Education Mobile Web Application on Patients With Uncontrolled Type 2 Diabetes | N/A | The Reading Hospital and Medical Center | 49 mi |
| Multi-Center Clean Air Randomized Controlled Trial in COPD | Phase 3 | JHSPH Center for Clinical Trials | 49 mi |
| A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | Phase 3 | Pfizer | 49 mi |
| Study of GS-0272 in Participants With Rheumatoid Arthritis | Phase 1 | Gilead Sciences | 50 mi |
| Prospective Study to Assess a Diagnostic Aid for Cancer | — | Harbinger Health | 50 mi |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | Phase 3 | Takeda | 50 mi |
| A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain | Phase 2 | Eli Lilly and Company | 50 mi |